Early-onset Generalized Limb-onset Dystonia

🏷

Classifications

Harrison's Part

👪

Inheritance

1

Autosomal dominant with reduced penetrance HP:0000006

Autosomal dominant transmission of a single recurrent TOR1A allele. Each child of an affected individual has a 50% chance of inheriting the variant, but only about 30% of those who inherit it ever develop dystonia. Reduced penetrance is the central counselling fact of this disease, not a caveat on it: most carriers in a pedigree are clinically normal, so an unaffected parent or sibling cannot be assumed to be a non-carrier, and apparently sporadic cases are frequently inherited. Expressivity among those who do manifest is also variable, so an affected child may be more or less severely affected than the transmitting parent.

Autosomal dominant inheritance Penetrance: INCOMPLETE Expressivity: VARIABLE

Show evidence (4 references)

PMID:20301665 SUPPORT Human Clinical

"DYT-TOR1A is inherited in an autosomal dominant manner."

GeneReviews states the mode of inheritance.

PMID:20301665 SUPPORT Human Clinical

"The penetrance for the TOR1A c.907_909delGAG deletion is approximately 30%; thus, on average, 30% of individuals who inherit the TOR1A c.907_909delGAG deletion develop dystonia and 70% do not develop dystonia."

Quantifies penetrance directly and states the complementary 70% non-manifesting fraction, which is the fact that governs counselling.

PMID:23649720 SUPPORT INDIRECT Other

"DYT1 dystonia is transmitted as an autosomal-dominant trait with a penetrance of about 30%."

Independent corroboration of the penetrance figure from the international classification consensus, cited here because a single-source penetrance claim is exactly the kind that should be checked against a second authority. Graded OTHER because the publication is an expert consensus statement rather than a study reporting data, and INDIRECT because the sentence restates established literature rather than measuring penetrance.

+ 1 more reference

?

Discussions and Knowledge Gaps

2

Mouse models show perinuclear nuclear-envelope blebs and human patient-derived neurons do not, while heterozygous mice show no pathology at all. Which nuclear-envelope lesion is the one that occurs in patients, and does any of the mouse pathology apply to the human disease?

HUMAN MODEL MISMATCH dyt1_nuclear_envelope_model_mismatch

Attached to

pathophysiology#Neuronal Nuclear Envelope Disruption experimental_models#Patient-derived cholinergic motor neurons animal_models#Tor1a heterozygous GAG-deletion knock-in mouse

This is not a generic species caveat but a specific, twofold mismatch that bears on the entry's central mechanistic claim. First, zygosity. Patients are heterozygous. Mice heterozygous for the identical deletion show no pathology, so every mouse result supporting the nuclear-envelope account comes from a homozygous null, homozygous knock-in, or conditional-deletion genotype that no patient has. Second, morphology. Where the mouse shows perinuclear blebs or herniations, patient-derived cholinergic motor neurons carrying the heterozygous deletion show a thickened lamina, disrupted nuclear shape and LMNB1 dysregulation, and explicitly lack the blebs. Both are nuclear envelope pathology and it would be easy to treat them as the same finding, but they are different lesions, and the mechanism inferred from one does not automatically transfer. The consequence for reading this entry: the Neuronal Nuclear Envelope Disruption node is well supported as a category and poorly resolved as a specific lesion. No patient brain tissue has shown either morphology in vivo, which is what would settle it. The human model is not simply better than the mouse either - cultured motor neurons lack the striatal circuitry the disease is about, and the striatal cholinergic interneuron evidence runs the other way, existing in mouse and in postmortem patient striatum but not in the iPSC system.

Recorded as HUMAN_MODEL_MISMATCH rather than KNOWLEDGE_GAP because the evidence is not absent: both lesions are well documented in their respective systems, and the open question is translational validity.

Why do roughly 70% of TOR1A GAG-deletion carriers never develop dystonia, when functional imaging shows the same network abnormality in manifesting and non-manifesting carriers alike?

KNOWLEDGE GAP dyt1_reduced_penetrance_determinants

Attached to

pathophysiology#Basal Ganglia and Cerebellothalamocortical Network Dysfunction inheritance#Autosomal dominant with reduced penetrance genetic#TOR1A p.D216H

Reduced penetrance is usually treated as a counselling fact, but here it is also the sharpest mechanistic question in the disease, because the obvious candidate explanation has been excluded. Reduced striatal GABA and dopamine receptor availability, increased lentiform, supplementary motor area and cerebellar metabolism, and an abnormal cerebellothalamocortical pathway are all present in carriers irrespective of whether they manifest. So the network abnormality this entry places immediately upstream of the movement disorder is not sufficient to produce it. The systematic review's proposal is that the distinguishing factor lies in the distal thalamocortical segment, disrupted in non-manifesting carriers in a way that may prevent abnormal impulses reaching cortex, together with larger putaminal volumes that appear compensatory and a correspondingly reduced response to plasticity-inducing protocols. That is a hypothesis generated from cross-sectional imaging of small cohorts rather than an established mechanism. One genetic modifier is established, and it is a partial answer rather than none. The TOR1A coding polymorphism D216H (rs1801968) modifies penetrance of the GAG deletion: the 216H allele carried in trans is highly protective, D216 in cis appears to be required for the deletion to be penetrant at all, and the derived penetrance estimates are about 35% for a carrier with D216 in trans against about 3% for one carrying 216H. It is curated as a MODIFIER record in `genetic:`. What keeps this a knowledge gap is the size and the scope of that answer, stated by the same study that found it. The 216H allele has a potent effect but explains only a small proportion of the reduced penetrance, so most of the 70% is still unaccounted for. And nearly all manifesting carriers were D216 homozygotes, which means the modifier says nothing about the second question sitting beside penetrance - why, among those who do manifest, severity ranges from writer's cramp that never spreads to generalized dystonia. Beyond D216H this entry records no determinant of penetrance, and none was found in the sources fetched for it: no environmental trigger, no developmental variable, and no further modifier locus. Until this is settled, the final edge in this entry - from network dysfunction to dystonia - is an association plus a therapeutic argument, and the entry says so at that node rather than implying a closed causal chain.

Show evidence (2 references)

PMID:17503336 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Although the 216H allele has a potent effect, it explains only a small proportion of the reduced penetrance associated with carrying the DYT1 GAG-deletion mutation."

The authors' own bound on how much their modifier explains, which is what keeps reduced penetrance an open question after D216H rather than a solved one. Cited on the gap itself so that a reader who sees the MODIFIER record in `genetic:` does not conclude the gap has closed.

PMID:17503336 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Also, almost all manifesting carriers, regardless of severity, were homozygous for the D216 allele, so factors moderating the extent of disease expression in these individuals remain unknown."

States the second, distinct gap in the authors' own words: the modifier stratifies who manifests, not how severely. This is the sentence behind the variable-expressivity half of this discussion, which is separate from the penetrance half and is not addressed by D216H at all.

⚙

Pathophysiology

8

Heterozygous TOR1A GAG Deletion

A heterozygous in-frame three-base-pair deletion, c.907_909delGAG, in exon 5 of TOR1A. It removes one of a pair of glutamate residues from a conserved C-terminal region of torsinA without shifting the reading frame, so a near-full-length protein is made. More than 98% of affected individuals carry this same allele, which is unusual for a Mendelian disease and is why the entry can describe one variant rather than a spectrum.

neuron CL:0000540

TOR1A hgnc:3098

Genetic context allele_type: DELETION variant_origin: GERMLINE zygosity: HETEROZYGOUS functional_impact_category: LOSS_OF_FUNCTION

cofactor-dependent torsinA ATP hydrolysis GO:0016887 ↓ DECREASED

Downstream

Impaired TorsinA AAA+ ATPase Function Deletion of the glutamate within the conserved region compromises the nucleotide-dependent cycle of the AAA+ domain, which is the proximate molecular consequence of the allele.

Show evidence (3 references)

PMID:9288096 SUPPORT Human Clinical

"This deletion results in loss of one of a pair of glutamic-acid residues in a conserved region of a novel ATP-binding protein, termed torsinA."

The original gene-identification paper states the molecular nature of the lesion - single glutamate loss from a conserved region of an ATP-binding protein - which is the definition of this node.

PMID:20301665 SUPPORT Human Clinical

"More than 98% of affected individuals have the 3-bp deletion c.907_909delGAG involving the highly conserved GAGGAG sequence in exon 5."

Supplies the precise coding change and establishes that essentially the whole disease is attributable to this one allele.

PMID:33468570 SUPPORT INDIRECT BACKGROUND Human Clinical

"It is caused by a heterozygous mutation in Torsin A (TOR1A), a gene encoding a membrane-embedded ATPase."

Supports the molecular-function binding on this node by naming what the gene disrupted here encodes: the disease-causing allele is a heterozygous TOR1A mutation, and TOR1A's product is an ATPase, so ATP hydrolysis is the activity the deletion acts on. INDIRECT because the sentence asserts the gene-to-activity link rather than the reduction itself, which the conserved-region glutamate loss above and the cofactor-cycle evidence on the next node carry. Graded HUMAN_CLINICAL because the quoted sentence states the human genetic aetiology, with quote_role BACKGROUND because it is this in-vitro paper's framing of established genetics rather than its own result.

Impaired TorsinA AAA+ ATPase Function

TorsinA is an AAA+ ATPase resident in the endoplasmic reticulum lumen and the contiguous perinuclear space. Unlike most AAA+ proteins it lacks a complete catalytic site of its own and depends on the membrane cofactors LAP1 (nuclear envelope) and LULL1 (bulk ER), each of which supplies an arginine finger to complete the active site and trigger hydrolysis. The disease deletion sits in the region that mediates this regulated cycle, so the mutant protein is impaired in the cofactor-driven ATPase activity through which torsinA does its work. The functional readout that matters is not the catalytic rate in isolation but the ability to rescue nuclear envelope defects in torsin-deficient cells.

cofactor-dependent torsinA ATP hydrolysis GO:0016887 ↓ DECREASED

Downstream

Neuronal Nuclear Envelope Disruption Loss of regulated torsinA ATPase activity at the nuclear envelope removes the activity whose absence produces the membrane lesion in the next node.

Show evidence (3 references)

PMID:28814508 SUPPORT In Vitro

"TorsinA is an essential AAA+ ATPase requiring LAP1 or LULL1 as cofactors."

Establishes the enzyme class and the obligate cofactor dependence that defines how torsinA activity is regulated.

PMID:28814508 SUPPORT In Vitro

"Engagement of the oligomer by LAP1 triggers ATP hydrolysis and rapid complex disassembly."

Describes the cofactor-triggered hydrolysis step, supporting the characterization of torsinA function as a regulated ATPase cycle rather than constitutive catalysis.

PMID:28814508 SUPPORT INDIRECT In Vitro

"These Torsin mutants are severely compromised in their ability to rescue nuclear envelope defects in Torsin-deficient cells, suggesting that TorsinA homo-oligomers play a key role in vivo."

Links loss of correct torsin assembly to failure of nuclear envelope maintenance, which is the edge this node asserts. INDIRECT because the mutants studied are engineered oligomerization-interface variants rather than the disease GAG deletion, so the inference to the patient allele is a step removed.

Neuronal Nuclear Envelope Disruption

Loss of torsinA function produces abnormal nuclear envelope architecture that is, strikingly, restricted to neurons even though TOR1A is widely expressed - the classic statement of the tissue-specificity problem in this disease. In mouse null and homozygous knock-in neurons the lesion takes the form of perinuclear membrane blebs or herniations. In human patient-derived cholinergic motor neurons carrying the heterozygous deletion the lesion instead appears as a markedly thickened nuclear lamina with disrupted nuclear morphology and LMNB1 dysregulation, without the blebs. Both are nuclear envelope pathology; they are not the same lesion, and the entry does not treat the mouse morphology as established in humans. See the HUMAN_MODEL_MISMATCH discussion.

neuron CL:0000540

nuclear envelope organization GO:0006998 ↓ DECREASED

Experimental models

Patient-derived cholinergic motor neurons IPSC DERIVED MODEL Reproduces nuclear envelope pathology - markedly thickened nuclear lamina, disrupted nuclear morphology, LMNB1 upregulation and mislocalization - but not the perinuclear blebs that are the signature lesion in the mouse models. It supports the node while contradicting the mouse's account of what the node looks like in human cells.

Animal models

TorsinA-null and homozygous knock-in mouse neurons Mouse recapitulates Demonstrates the nuclear envelope lesion and its neuron-selectivity, and establishes its developmental timing.

Downstream

Impaired Nucleocytoplasmic Transport A disordered nuclear envelope and lamina compromise the interface across which all nuclear import and export occurs.

Maturation-Dependent Disruption of Neuronal Development The envelope lesion arises in postmigratory embryonic neurons and worsens with maturation, tying the cellular defect to a developmental window rather than to ongoing adult injury.

Show evidence (4 references)

PMID:16364897 SUPPORT Model Organism

"contain severely abnormal nuclear membranes, although non-neuronal cell types appear normal"

Establishes both the nuclear membrane lesion and its neuron-selectivity in torsinA-null and knock-in mice, which is the core claim of this node.

PMID:16364897 SUPPORT Model Organism

"These observations demonstrate that neurons have a unique requirement for nuclear envelope localized torsinA function and suggest that loss of this activity is a key molecular event in the pathogenesis of DYT1 dystonia."

States the authors' inference that nuclear-envelope-localized torsinA function is the relevant activity, supporting placement of this node on the main causal chain.

PMID:33468570 SUPPORT In Vitro

"markedly thickened nuclear lamina, disrupted nuclear morphology"

Supplies the human counterpart of the envelope lesion in patient-derived motor neurons carrying the heterozygous deletion, which is what licenses this node for the human disease rather than only for mouse models.

+ 1 more reference

Impaired Nucleocytoplasmic Transport

Patient-derived DYT1 motor neurons show impaired bidirectional traffic across the nuclear envelope, affecting both protein import and export and the export of mRNA. A specific molecular correlate has been identified: RANBP17, an importin-beta superfamily nuclear transport receptor, is strongly downregulated in DYT1 motor neurons, and restoring it rescues both the transport defect and the neurodevelopmental phenotype. That rescue is what makes this node causal rather than merely correlated, and it places impaired transport upstream of the developmental abnormality rather than beside it.

patient-derived cholinergic motor neuron CL:0000100

nucleocytoplasmic transport GO:0006913 ↓ DECREASED protein import into the nucleus in DYT1 motor neurons GO:0006606 ↓ DECREASED mRNA export from the nucleus in DYT1 motor neurons GO:0006406 ↓ DECREASED

Experimental models

Patient-derived cholinergic motor neurons IPSC DERIVED MODEL Measures impaired transport of both protein and mRNA cargo in human cells carrying the patient genotype, and identifies RANBP17 loss as its molecular correlate with a rescue experiment.

Downstream

Maturation-Dependent Disruption of Neuronal Development Restoring nucleocytoplasmic transport by RANBP17 overexpression rescues the neurodevelopmental deficits of DYT1 motor neurons, which is direct evidence that the transport defect is upstream of the developmental one.

Show evidence (3 references)

PMID:33468570 SUPPORT In Vitro

"impaired nucleocytoplasmic transport (NCT) of mRNAs and proteins"

Establishes the transport defect in human patient-derived neurons and that it affects both cargo classes.

PMID:38438257 SUPPORT In Vitro

"we identified that the expression level of RANBP17, a RAN-binding protein crucial for NCT regulation, exhibited a significant reduction in DYT1 MNs"

Identifies the specific transport receptor whose loss accompanies the defect, giving the node a molecular handle rather than a phenomenological one.

PMID:38438257 SUPPORT In Vitro

"the overexpression of RANBP17 emerged as a substantial mitigating factor, effectively restoring impaired NCT activity and rescuing neurodevelopmental deficits observed in DYT1 MNs"

A rescue experiment, which is the strongest available support for the downstream edge to the developmental node: correcting transport corrects development.

Maturation-Dependent Disruption of Neuronal Development

The consequences of torsinA loss are tied to a developmental window rather than to progressive adult injury. Nuclear envelope abnormalities appear in postmigratory embryonic neurons and worsen as those neurons mature; in conditional mouse mutants dystonic movements emerge during juvenile CNS maturation; and patient-derived motor neurons show reduced neurite length and branching. This node is why the disease is described as functional and developmental rather than degenerative, and it is the mechanistic counterpart of the clinical observation that symptoms begin in childhood, spread over a few years, and then persist without shortening life span.

developing neuron CL:0000540

neuron projection development GO:0031175 ↓ DECREASED

Animal models

Forebrain conditional torsinA knockout mouse Mouse recapitulates Shows that the phenotype is timed to juvenile CNS maturation rather than present from birth or acquired in adulthood, matching the childhood onset of the human disease.

Downstream

Striatal Cholinergic Interneuron Dysfunction The maturing dorsal striatum is where the developmental requirement for torsinA is most stringent, and its cholinergic interneurons are the cell type that fails.

Show evidence (3 references)

PMID:16364897 SUPPORT Model Organism

"These membrane abnormalities develop in postmigratory embryonic neurons and subsequently worsen with further neuronal maturation, a finding evocative of the developmental dependence of DYT1 dystonia."

States the developmental timing of the cellular lesion and explicitly ties it to the developmental dependence of the human disease.

PMID:26052670 SUPPORT Model Organism

"causes dystonic-like twisting movements that emerge during juvenile CNS maturation"

Shows the behavioural phenotype itself is maturation-timed rather than present from birth or acquired in adulthood.

PMID:33468570 SUPPORT In Vitro

"show reduced neurite length and branches"

Supplies the human cellular neurodevelopmental readout that the RANBP17 rescue experiment later corrects.

Striatal Cholinergic Interneuron Dysfunction

Dorsal striatal large cholinergic interneurons have a distinctive requirement for torsinA during striatal maturation. In mice with conditional forebrain deletion, the emergence of dystonic movements coincides with selective loss of these cells, and the survivors are morphologically, electrophysiologically and connectionally abnormal. Cholinergic abnormalities are also present in postmortem striatum from DYT1 patients, which is the main piece of human tissue evidence anywhere in this chain. Note the terminological hazard: the mouse model shows selective degeneration of this one interneuron class, which is not the same as the disease being a neurodegeneration - the human disorder has no overt neuropathological signature.

dorsal striatal large cholinergic interneuron CL:0020007

striatal cholinergic synaptic transmission GO:0007271 ⚠ ABNORMAL

dorsal striatum UBERON:0002435

Animal models

Forebrain conditional torsinA knockout mouse Mouse recapitulates Identifies the selectively vulnerable cell type and characterizes the surviving population as morphologically, electrophysiologically and connectionally abnormal.

Downstream

Reduced Striatal Dopamine Release Acetylcholine released by striatal cholinergic interneurons drives dopamine release from nigrostriatal terminals through nicotinic receptors, so cholinergic interneuron dysfunction propagates directly into the dopaminergic readout.

Basal Ganglia and Cerebellothalamocortical Network Dysfunction Cholinergic interneurons are the principal local modulator of striatal output, so their dysfunction alters basal ganglia network signalling independently of the dopaminergic arm.

Show evidence (3 references)

PMID:26052670 SUPPORT Model Organism

"The onset of these movements coincides with selective degeneration of dorsal striatal large cholinergic interneurons (LCI), and surviving LCI exhibit morphological, electrophysiological, and connectivity abnormalities."

Establishes both the selective vulnerability of this cell type and that the surviving population is functionally abnormal, which is the substance of this node.

PMID:26052670 SUPPORT Human Clinical

"we identify cholinergic abnormalities in postmortem striatal tissue from DYT1 dystonia patients"

Human postmortem corroboration that the cholinergic abnormality is not a mouse-only finding. Graded HUMAN_CLINICAL because this specific claim rests on patient tissue, whereas the same paper's mouse results are graded MODEL_ORGANISM; the paper mixes sources and the items are split accordingly.

PMID:26052670 SUPPORT Model Organism

"murine dystonic-like movements are reduced significantly with an antimuscarinic agent used clinically"

Pharmacological validation of the cholinergic node: blocking muscarinic signalling reduces the movements, which is also the mechanistic rationale for trihexyphenidyl in patients.

Reduced Striatal Dopamine Release

Striatal dopamine signalling is abnormal in both directions of evidence. Knock-in mice carrying the heterozygous deletion show significantly reduced evoked dopamine release, and DYT1 patients show reduced striatal D2 receptor availability. The link to the cholinergic node above is mechanistic rather than merely associative: trihexyphenidyl restores dopamine release in Dyt1 mice through a nicotinic-receptor-dependent route, which is the clearest account available of how the clinically preferred drug works. Levodopa, by contrast, does not increase dopamine release in these mice, matching the clinical observation that DYT1 dystonia is not dopa-responsive.

nigrostriatal dopaminergic neuron CL:0000700

striatal dopamine secretion GO:0014046 ↓ DECREASED

striatum UBERON:0002435

Animal models

Tor1a heterozygous GAG-deletion knock-in mouse Mouse recapitulates Directly measures reduced evoked dopamine release in the striatum of a mouse carrying the human allele, by ex vivo fast-scan cyclic voltammetry and in vivo microdialysis.

Downstream

Basal Ganglia and Cerebellothalamocortical Network Dysfunction Reduced dopaminergic drive and reduced D2 receptor availability alter the balance of striatal output pathways, feeding the network abnormality seen on imaging.

Show evidence (4 references)

PMID:30707939 SUPPORT Model Organism

"we found that DA release was significantly reduced in Dyt1 knockin mice"

Direct measurement of the reduced dopamine release that defines this node, in the mouse carrying the disease allele.

PMID:30707939 SUPPORT INDIRECT Model Organism

"Previous studies have demonstrated reductions in striatal D2 receptor density and abnormalities in DA metabolites in DYT1 patients."

Records the human counterpart of the mouse finding. INDIRECT because the sentence is this paper's summary of prior patient literature rather than a result it measures; the paper's own data are rodent, which is why the item is graded MODEL_ORGANISM.

PMID:30707939 SUPPORT Model Organism

"THP restored DA release in Dyt1 mice through a nAChR-dependent mechanism"

Establishes the cholinergic-to-dopaminergic mechanistic link asserted by the upstream edge, and supplies the mechanism of action for trihexyphenidyl.

+ 1 more reference

Basal Ganglia and Cerebellothalamocortical Network Dysfunction

The convergence point, and the least mechanistically closed node in the entry. Functional imaging in DYT1 carriers shows reduced striatal GABA and dopamine receptor availability, increased metabolic activity in the lentiform nucleus, supplementary motor area and cerebellum, and an abnormal cerebellothalamocortical pathway. Notably these changes are present in carriers irrespective of whether they manifest dystonia, so network abnormality alone is not sufficient for disease - what distinguishes manifesting from non-manifesting carriers appears to involve the distal thalamocortical segment and compensatory putaminal changes. That is the imaging-level correlate of 30% penetrance. What remains unestablished is the causal step from this network state to the dystonic movement itself; the entry asserts the association and stops there.

globus pallidus UBERON:0001875 striatum UBERON:0002435

Downstream

Limb-onset dystonia Abnormal motor network output is the presumed proximate cause of the dystonic postures and movements. This edge is the weakest in the chain and is supported by association and by the therapeutic response to pallidal stimulation rather than by a demonstrated causal path.

Show evidence (3 references)

PMID:37165749 SUPPORT Human Clinical

"All DYT1 gene carriers irrespective of clinical penetrance have reduced striatal GABA, dopamine receptors and increased metabolic activity in the lentiform nucleus, supplementary motor area, and cerebellum in addition to an abnormal cerebellothalamocortical pathway."

The systematic review's primary result, establishing both the network abnormality and the critical observation that it is present in non-manifesting carriers too.

PMID:37165749 SUPPORT Human Clinical

"we propose that DYT1 dystonia is a cerebellostriatothalamocortical network disorder affecting either the structure or function of the different structures or nodes in the network"

States the review's synthesis, which is the framing this node adopts - a distributed network disorder rather than a single-structure lesion.

PMID:26052670 SUPPORT INDIRECT Human Clinical

"primary dystonia results from abnormal functioning of a structurally intact central nervous system"

Supports the characterization of the network state as functional rather than structural-degenerative, which is the distinction this entry is built around. INDIRECT because the sentence states the field's accepted framing in the paper's introduction rather than reporting a measurement.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

10

Limbs 1

Hip dislocation HP:0002827

Show evidence (1 reference)

PMID:20301665 SUPPORT INDIRECT REVIEW SYNTHESIS Other

"Physiatry and physical therapy to tailor exercise programs to maintain function and prevent secondary orthopedic complications (e.g., joint contractures, hip dislocation, and/or kyphoscoliosis), provide adaptative aids, and support and maintain ambulation"

Names hip dislocation among the secondary orthopedic complications that rehabilitation is directed at preventing, and ties the prevention goal to maintaining ambulation. INDIRECT and OTHER as above.

Musculoskeletal 2

Joint contracture HP:0034392

Show evidence (1 reference)

PMID:20301665 SUPPORT INDIRECT REVIEW SYNTHESIS Other

"Timely medical intervention and appropriate referral for consideration of globus pallidus internus deep brain stimulation is recommended to optimally treat manifestations, minimize disability, and prevent long-term orthopedic complications such as joint contractures or spine deformities."

Names joint contracture as a long-term orthopedic complication of untreated disease. INDIRECT because the sentence is framed as a treatment goal, and the occurrence of the complication follows from its being something treatment is meant to prevent; OTHER because a GeneReviews management recommendation is expert guidance rather than a reported study.

Kyphoscoliosis HP:0002751

Show evidence (1 reference)

PMID:20301665 SUPPORT INDIRECT REVIEW SYNTHESIS Other

"Physiatry and physical therapy to tailor exercise programs to maintain function and prevent secondary orthopedic complications (e.g., joint contractures, hip dislocation, and/or kyphoscoliosis), provide adaptative aids, and support and maintain ambulation"

Names kyphoscoliosis specifically among the secondary orthopedic complications that physiatry and physical therapy are directed at, which is more precise than the same chapter's "spine deformities" phrasing. INDIRECT and OTHER for the same reasons as the contracture item.

Nervous System 6

Limb-onset dystonia Limb dystonia HP:0002451

Onset: CHILDHOOD

Sequelae: Generalized dystonia

Show evidence (5 references)

PMID:20301665 SUPPORT Human Clinical

"Dystonia typically begins in a leg or arm. While onset can occur in axial, cervical, or cranial regions, these are far less common than onset in a limb."

States the limb-onset pattern and that non-limb onset is much less common, which is the defining clinical fact of this entity.

PMID:20301665 SUPPORT Human Clinical

"DYT1-TOR1A is an isolated dystonia with onset typically in childhood (median age of onset: 9 years; interquartile range: 7-12 years)."

Supplies the onset age distribution and records that the dystonia is isolated rather than part of a complex syndrome.

PMID:20301665 SUPPORT REVIEW SYNTHESIS Human Clinical

"About 5% of individuals have onset after age 30 years."

Quantifies the adult-onset minority, which bounds how far the entity's "early-onset" name can be relied on diagnostically. REVIEW_SYNTHESIS because GeneReviews is summarising the published cohorts rather than reporting its own series; evidence_source stays HUMAN_CLINICAL because the figure describes human patients.

+ 2 more references

Generalized dystonia HP:0007325

Course: PROGRESSIVE

Sequelae: Joint contracture Kyphoscoliosis Hip dislocation

Show evidence (2 references)

PMID:20301665 SUPPORT Human Clinical

"Dystonia can also spread to other body regions, progressing over months to years to "generalized dystonia" involving other limbs and the trunk. In individuals with onset in a leg, progression of dystonia is common."

States the generalization process, its time course, and that leg onset predicts it - the basis for the PROGRESSIVE clinical course.

PMID:20301665 SUPPORT Human Clinical

"Once dystonic movements appear, they usually persist lifelong."

Establishes persistence, which together with the absence of degeneration characterizes the disease as a stable acquired motor disability rather than a progressive neurological decline.

Writer's cramp HP:0002356

Show evidence (1 reference)

PMID:20301665 SUPPORT Human Clinical

"writer's cramp, characterized by tightening and/or posturing of the hand or arm with writing"

Describes the task-specific upper-limb presentation.

Persistent focal dystonia OCCASIONAL HP:0004373

Show evidence (1 reference)

PMID:20301665 SUPPORT Human Clinical

"In approximately 20% of individuals dystonia remains restricted to a single body region, most often as writer's cramp."

Supplies both the phenotype and the ~20% figure, which is the basis for the OCCASIONAL (5-29%) frequency band rather than a separate qualitative judgement.

Gait disturbance HP:0001288

Show evidence (1 reference)

PMID:20301665 SUPPORT Human Clinical

"presenting as a change in gait (e.g., foot inversion or abnormal flexion of the knee or hip)"

Describes the specific gait abnormality of leg-onset disease.

Largely preserved cognition with isolated executive dysfunction Impaired executive functioning HP:0033051

Show evidence (3 references)

PMID:28627117 SUPPORT REVIEW SYNTHESIS Human Clinical

"In idiopathic or DYT1 dystonia, cognition is largely intact with only isolated executive dysfunction."

States both halves of the claim - that cognition is broadly preserved and that the exception is executive function. REVIEW_SYNTHESIS because the publication is a literature review rather than a primary cognitive study.

PMID:28627117 SUPPORT REVIEW SYNTHESIS Human Clinical

"considered endophenotypes of the disorder because deficits are also shown by unaffected relatives and nonmanifesting carriers of the DYT1 mutation"

Supports treating the discrimination-threshold abnormalities as genotype-linked endophenotypes present without manifest dystonia, rather than as cognitive sequelae of the movement disorder.

PMID:28627117 SUPPORT REVIEW SYNTHESIS Human Clinical

"Anticholinergic medication in high doses can be associated with memory impairment in dystonia."

Supports the treatment-related confounder noted in the description, which matters because high-dose trihexyphenidyl is standard therapy here.

Other 1

Status dystonicus

Show evidence (1 reference)

PMID:20301665 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Status dystonicus, the most severe manifestation of dystonia that requires emergent hospitalization, can occur but is not common in DYT-TOR1A."

States the phenotype, its severity, the level of care it demands, and that it is uncommon in this specific genotype rather than in dystonia at large. REVIEW_SYNTHESIS because GeneReviews is summarising the reported cohorts.

🧬

Genetic Associations

2

TOR1A

Gene: TOR1A hgnc:3098 relationship_type: CAUSATIVE

Show evidence (4 references)

PMID:9288096 SUPPORT Human Clinical

"This study identifies the DYT1 gene on human chromosome 9q34 as being responsible for this dominant disease."

The gene-identification paper establishing the causal locus and the dominant mode of transmission.

PMID:9288096 SUPPORT Human Clinical

"Almost all cases of early-onset dystonia have a unique 3-bp deletion that appears to have arisen idependently in different ethnic populations."

Establishes that one recurrent allele accounts for nearly all disease and that it is recurrent rather than descended from a single global founder. Quoted verbatim including the source's typographical error in "idependently", as an evidence snippet must never be corrected.

PMID:20301665 SUPPORT Human Clinical

"The diagnosis of DYT-TOR1A is established in a proband with suggestive findings and a heterozygous pathogenic variant in TOR1A identified by molecular genetic testing."

States the diagnostic criterion and the heterozygous state of the causal variant.

+ 1 more reference

TOR1A p.D216H (Intragenic modifier of penetrance of the c.907_909delGAG allele. The 216H allele carried in trans is highly protective; the D216 allele in cis appears to be required for the deletion to be penetrant.)

Gene: TOR1A hgnc:3098 relationship_type: MODIFIER variant_origin: GERMLINE

Show evidence (3 references)

PMID:17503336 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Analysis of haplotypes demonstrated a highly protective effect of the H allele in trans with the GAG deletion; there was also suggestive evidence that the D216 allele in cis is required for the disease to be penetrant."

The result that establishes the modifier and, unusually, its phase dependence - protective in trans, permissive in cis. This is the sentence the MODIFIER classification rests on.

PMID:17503336 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"found the frequency of the 216H allele to be increased in GAG-deletion carriers without dystonia and to be decreased in carriers with dystonia, compared with the control individuals"

The underlying observation: the protective allele is enriched in non-manifesting carriers and depleted in manifesting ones, measured against controls. Cited separately from the haplotype analysis because it is the raw association rather than the phase-resolved inference drawn from it.

PMID:17503336 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Our findings establish, for the first time, a clinically relevant gene modifier of DYT1."

The authors' own characterization of what they found, which is where the MODIFIER relationship_type and the word "modifier" in this record come from rather than from a curator's paraphrase.

💊

Medical Actions

5

Bilateral pallidal deep brain stimulation

Action: bilateral globus pallidus internus deep brain stimulation Ontology label: Deep Brain Stimulation NCIT:C21024

Platform: Device

Chronic high-frequency electrical stimulation delivered through electrodes implanted bilaterally in the internal globus pallidus. This is the defining intervention for the disease and the reason DYT1 dystonia, despite having no disease-modifying therapy, is one of the more treatable severe movement disorders. Efficacy in generalized and segmental dystonia is established by a randomized sham-controlled trial, and DYT1-specific series report large sustained improvements in Burke-Fahn-Marsden movement scores. Shorter disease duration predicts better outcome, which is the practical argument for early referral rather than a last resort after years of failed medication. It is symptomatic: it modulates network output and does nothing about torsinA.

Mechanism Target:

Basal Ganglia and Cerebellothalamocortical Network Dysfunction — Stimulation is delivered into the pallidal output node of the network this entry identifies as the convergence point, altering its signalling. That the intervention works at this node is also the main indirect argument for placing the node on the causal path to the movement disorder.

Generalized dystonia — The clinical target: large reductions in Burke-Fahn-Marsden movement and disability scores across the generalized distribution.

Show evidence (8 references)

PMID:17093249 SUPPORT Human Clinical

"Bilateral pallidal neurostimulation for 3 months was more effective than sham stimulation in patients with primary generalized or segmental dystonia."

The randomized sham-controlled result, which is the highest-quality evidence available for this intervention and the reason it is stated without hedging.

PMID:17093249 SUPPORT Human Clinical

"Three months after randomization, the change from baseline in the mean (+/-SD) movement score was significantly greater in the neurostimulation group (-15.8+/-14.1 points) than in the sham-stimulation group (-1.4+/-3.8 points, P<0.001)."

Quantifies the effect against sham on the Burke-Fahn-Marsden movement subscore, the standard outcome measure in this field.

PMID:22811083 SUPPORT Human Clinical

"Pallidal DBS was well tolerated and highly effective, with mean Burke-Fahn-Marsden Dystonia Rating Scale movement scores improving from baseline by 61.5% (P < .001) at 1 year, 64.4% (P < .001) at 2 years, and 70.3% (P < .001) at the final follow-up visit"

DYT1-genotyped long-term outcome data, establishing that the benefit is large and sustained rather than transient - the sham-controlled trial above was only three months and was not genotype-restricted.

+ 5 more references

Trihexyphenidyl

Action: Pharmacotherapy NCIT:C15986

Agent: trihexyphenidyl CHEBI:9720

Platform: Small molecule

High-dose oral trihexyphenidyl, a non-selective muscarinic acetylcholine receptor antagonist, is the preferred small-molecule treatment. Its rationale is mechanistic rather than incidental: striatal cholinergic interneurons are the cell type implicated by the mouse work in this entry, and antimuscarinic treatment reduces dystonic movements in those mice. In Dyt1 knock-in mice trihexyphenidyl also restores the reduced striatal dopamine release, through a nicotinic-receptor-dependent route, which links the drug to two of the nodes above. Its limitation is tolerability: the doses needed are high and antimuscarinic side effects are dose-limiting, including memory impairment.

Mechanism Target:

Striatal Cholinergic Interneuron Dysfunction — Muscarinic blockade acts directly on the striatal cholinergic node, which is the node the drug's mechanism of action is defined against.

Reduced Striatal Dopamine Release — Trihexyphenidyl restores dopamine release in Dyt1 knock-in mice via nicotinic receptors, so it also acts on the dopaminergic node downstream.

Show evidence (3 references)

PMID:30707939 SUPPORT BACKGROUND Model Organism

"Trihexyphenidyl, a nonselective muscarinic receptor antagonist, is the small molecule drug of choice for the treatment of DYT1 dystonia, but it is poorly tolerated due to significant side effects."

States both the drug's first-line status in this specific disease and its tolerability limitation. Marked BACKGROUND because the sentence is the paper's framing of clinical practice, not a result of its rodent experiments; evidence_source stays MODEL_ORGANISM because the publication is a mouse study.

PMID:30707939 SUPPORT INDIRECT Model Organism

"THP restored DA release in Dyt1 mice through a nAChR-dependent mechanism, suggesting a mechanism of action for THP in the treatment of dystonia and identifying nAChRs as a therapeutic target."

Supplies the mechanism of action behind the second target_mechanisms link. INDIRECT because the demonstration is in mouse striatal slices and in vivo microdialysis, so its application to the human drug effect is an inference.

PMID:26052670 SUPPORT INDIRECT Model Organism

"murine dystonic-like movements are reduced significantly with an antimuscarinic agent used clinically"

Behavioural evidence that antimuscarinic treatment works on the movements themselves, not only on a neurochemical readout. INDIRECT because the result is in a conditional-knockout mouse rather than in patients.

Botulinum toxin chemodenervation

Action: botulinum toxin chemodenervation Ontology label: Botulinum Toxin Therapy NCIT:C157775

Platform: Other

Intramuscular botulinum neurotoxin injection into individually disabling dystonic muscles. In a generalized dystonia it cannot address the whole distribution, so its role here is adjunctive - targeting a residual focal problem, including one persisting after pallidal stimulation - rather than primary. It acts at the neuromuscular junction, the furthest possible point downstream of the torsinA lesion.

Mechanism Target:

Limb-onset dystonia — Blocks acetylcholine release at the neuromuscular junction of the injected muscle, reducing contraction in that muscle only. Purely symptomatic and distal to every mechanistic node in this entry.

Show evidence (1 reference)

PMID:28627117 SUPPORT INDIRECT REVIEW SYNTHESIS Human Clinical

"The successful treatment of dystonia with botulinum toxin injections or deep brain stimulation does not produce any major adverse effects on cognition."

The only quotable statement in the fetched reference set that bears on botulinum toxin in this disease. It establishes that the treatment is used and can be successful, and that it does not carry a cognitive penalty - relevant given that the oral alternative does. INDIRECT because the sentence is about cognitive safety rather than motor efficacy, and no motor-efficacy quote for botulinum toxin in DYT1 specifically was found in the references fetched for this entry.

Physiatry and physical therapy

Action: physiatry and physical therapy Ontology label: Physical Therapy NCIT:C15302

Platform: Behavioral / lifestyle

Tailored exercise programmes, adaptive aids and gait support, directed by physical medicine and rehabilitation. Its purpose here is specific and worth stating precisely: it does not treat the dystonia, it treats what sustained dystonic posturing does to the musculoskeletal system. That makes it the one intervention in this entry aimed at the secondary complications - contracture, hip displacement, spinal deformity - rather than at the movement disorder, which is also why it runs alongside pallidal stimulation rather than competing with it. Note the direction of the contrast with the environmental record in this entry: the rehabilitation pathway is active exercise and adaptation, whereas immobilizing a dystonic part can worsen the dystonia.

Mechanism Target:

Joint contracture — Range-of-motion and stretching programmes are directed at preventing fixed contracture in joints held in sustained dystonic posture.

Kyphoscoliosis — Postural and trunk-directed exercise is aimed at limiting the spinal deformity that asymmetric axial dystonic load produces during growth.

Hip dislocation — Positioning and strengthening are directed at keeping the hip loaded normally enough to prevent displacement.

Gait disturbance — Gait training and adaptive aids support and maintain ambulation, which the source names as an explicit goal of physical therapy. Relevant because gait is also the feature that responds least well to pallidal stimulation and so is often the residual disability.

Show evidence (1 reference)

PMID:20301665 SUPPORT DIRECT REVIEW SYNTHESIS Other

"Physiatry and physical therapy to tailor exercise programs to maintain function and prevent secondary orthopedic complications (e.g., joint contractures, hip dislocation, and/or kyphoscoliosis), provide adaptative aids, and support and maintain ambulation"

Establishes the intervention, its four stated goals, and the three specific complications it is directed against - which is where this treatment's target_mechanisms links come from rather than from a curator's inference about what rehabilitation is for. Graded OTHER and REVIEW_SYNTHESIS as expert management guidance. Quoted verbatim including the chapter's "adaptative" for adaptive.

Occupational therapy

Action: occupational therapy Ontology label: Occupational Therapy NCIT:C121351

Platform: Behavioral / lifestyle

Therapy directed at the fine motor tasks of daily life - feeding, grooming, dressing and writing. It matters disproportionately in this disease because writing is both a common presenting complaint and, in the roughly one in five patients whose dystonia stays focal, often the whole of the disability.

Mechanism Target:

Writer's cramp — Writing is one of the fine motor skills the source names as an explicit target of occupational therapy, and writer's cramp is the form this entry's task-specific upper-limb dystonia takes.

Show evidence (1 reference)

PMID:20301665 SUPPORT DIRECT REVIEW SYNTHESIS Other

"occupational therapy to address fine motor skills (e.g., feeding, grooming, dressing, and writing)"

Names the intervention and the fine motor domains it addresses, including writing, which is the basis for the link to writer's cramp. Graded OTHER and REVIEW_SYNTHESIS as expert management guidance.

🌍

Environmental Factors

1

Immobilization of a dystonic body part by bracing or casting

The one iatrogenic circumstance GeneReviews tells clinicians to avoid in this disease. Splinting, bracing or casting a limb affected by dystonia - the intuitive orthopaedic response to a fixed abnormal posture, and a plausible one given that contracture and spinal deformity are real complications here - can make the dystonia worse. It is modelled as an environmental influence rather than buried in a treatment note because it is an exposure the patient undergoes, it has a direction of effect, and it acts on a named node of this entry's pathograph. The exception the source preserves is "unless medically necessary": this is not a prohibition, for instance after a fracture, but a caution against immobilization chosen as a way of managing the dystonia itself. The practical corollary sits with the rehabilitation entries in `treatments:` - the GeneReviews management pathway is active exercise programmes and adaptive aids, not restraint.

Show evidence (1 reference)

PMID:20301665 SUPPORT DIRECT REVIEW SYNTHESIS Other

"Unless medically necessary, avoid immobilization with bracing or casting of the parts of the body affected by dystonia, which can worsen dystonia."

The GeneReviews "Agents/circumstances to avoid" recommendation, which is the entire basis for this record. Graded OTHER because it is expert management guidance rather than a reported study, and REVIEW_SYNTHESIS because the chapter is synthesising practice it did not itself measure.

Mechanism Target:

EXACERBATES Limb-onset dystonia — Immobilizing the affected part worsens the dystonia in that part. The link is drawn to the limb-onset node because the limb is what gets braced or cast, but the source states it for any body region affected by dystonia.

Show evidence (1 reference)

PMID:20301665 SUPPORT DIRECT REVIEW SYNTHESIS Other

"Unless medically necessary, avoid immobilization with bracing or casting of the parts of the body affected by dystonia, which can worsen dystonia."

States the exacerbating effect of the exposure on the dystonia directly, which is what the EXACERBATES predicate on this link asserts, and preserves the medical-necessity exception.

🔬

Diagnosis

1

Targeted TOR1A molecular genetic testing

The diagnosis is established by finding a heterozygous pathogenic TOR1A variant in a proband with a suggestive clinical picture. This disease is unusually favourable for targeted testing rather than panel or exome sequencing, because more than 98% of affected individuals carry the same c.907_909delGAG allele - so a single-variant assay answers the question in nearly every case, and a negative targeted result is informative rather than merely uninformative. Two consequences of the genetics govern how the result is read, and both are curated elsewhere in this entry. Penetrance is about 30%, so identifying the variant in a relative predicts dystonia in a minority of carriers and an unaffected parent cannot be assumed to be a non-carrier. And about 5% of affected individuals present after age 30, so a later presentation does not exclude the diagnosis.

targeted TOR1A single-variant molecular genetic testing NCIT:C15709

NCIT:C15709 Genetic Testing was checked against cache/ncit/terms.csv for its label and against the treatmentactionterm enum cache for membership in the dynamic enum that diagnosis_term binds to, which is reachable from NCIT:C25218 Clinical Intervention or Procedure. preferred_term carries the specificity the action term does not - that the assay is targeted at one variant in one gene rather than a broad genomic test. A levodopa trial to exclude dopa-responsive dystonia was considered as a second diagnostic item and is deliberately not curated, because no fetched source states it as a diagnostic step. The GeneReviews chapter does not mention levodopa at all, and the only fetched reference that does (PMID:30707939) is a mouse study whose levodopa content is a methods paragraph plus the result that levodopa does not increase striatal dopamine release. That result is curated where it belongs, on the Reduced Striatal Dopamine Release node, and it supports the pharmacological contrast with dopa-responsive dystonia without supporting a recommendation to perform a trial. Adding the item would have meant asserting a diagnostic pathway from a mouse experiment.

Show evidence (2 references)

PMID:20301665 SUPPORT DIRECT Human Clinical

"The diagnosis of DYT-TOR1A is established in a proband with suggestive findings and a heterozygous pathogenic variant in TOR1A identified by molecular genetic testing."

States the diagnostic criterion - clinical suspicion plus a heterozygous pathogenic TOR1A variant on molecular testing - which is what this diagnostic item is. The same sentence is cited on the TOR1A genetic record, where it supports the gene-disease claim; here it supports the testing pathway, and evidence_source is HUMAN_CLINICAL in both places because the publication's grading cannot change with the use made of the quote.

PMID:20301665 SUPPORT INDIRECT Human Clinical

"More than 98% of affected individuals have the 3-bp deletion c.907_909delGAG involving the highly conserved GAGGAG sequence in exon 5."

The allelic homogeneity that makes targeted single-variant testing an adequate first-line strategy here, where in most Mendelian diseases it would not be. INDIRECT because the sentence reports the allele distribution and the testing strategy follows from it rather than being stated.

📊

Prevalence

2

Ashkenazi Jewish population

Carrier Frequency 16.7–50.0 per 100,000 1–9 per 10,000 (carriers)

A frequency of the founder GAG-deletion mutation, not disease prevalence. The reported 1/6,000 to 1/2,000 range converts to 16.7-50 per 100,000; no synthetic midpoint is assigned. Because penetrance is approximately 30%, the frequency of manifesting disease in this population is substantially lower than this figure, but the cited source does not report a manifesting rate and none is derived here. What measure_type should be is not fully resolved by the source, and the record is deliberately not written as though it were. The quoted sentence says only that "this dominant mutation" has a "current high frequency", and its closing clause speaks of "disease allele frequencies" - so whether 1/6,000-1/2,000 is a heterozygote (carrier) frequency or an allele frequency is left open, and the two differ by a factor of about two. CARRIER_FREQUENCY is recorded because PrevalenceMeasureEnum has no allele-frequency value (permissible values checked: POINT_PREVALENCE, BIRTH_PREVALENCE, LIFETIME_PREVALENCE, PERIOD_PREVALENCE, ANNUAL_INCIDENCE, CARRIER_FREQUENCY, CASES_IN_LITERATURE, UNKNOWN) and because for a heterozygous dominant allele the carriers are the heterozygotes the enum's own definition names. Treat the band as the magnitude the source supports, not as a resolved carrier rate.

Show evidence (1 reference)

PMID:7719342 SUPPORT Human Clinical

"its current high frequency (between 1/6,000 and 1/2,000)"

Supplies the carrier-frequency range for the founder allele in the Ashkenazi Jewish population.

Ashkenazi Jewish early-onset cases

Unknown Not yet documented

Not an occurrence rate but the founder share: more than 90% of early-onset idiopathic torsion dystonia in this population traces to one mutation that arose about 350 years ago. Recorded as a prevalence record because it governs how the carrier frequency above should be read, and marked UNKNOWN / NOT_YET_DOCUMENTED rather than converted into a rate it does not supply.

Show evidence (1 reference)

PMID:7719342 SUPPORT Human Clinical

"Our data show that the vast majority (> 90%) of early-onset ITD cases in the Ashkenazi population are due to a single founder mutation, which we estimate first appeared approximately 350 years ago."

Establishes the single-founder origin and its age, which is why carrier frequency in this population is high relative to the disease's rarity.

🔬

Clinical Trials

1

NCT00142259 NOT_APPLICABLE COMPLETED

The randomized, sham-controlled trial of bilateral internal globus pallidus stimulation in primary generalized or segmental dystonia reported by Kupsch and colleagues (PMID:17093249). Forty patients received an implanted device and were randomized to active or sham stimulation for three months, with blinded video assessment, followed by open-label active stimulation for all.

Target Phenotypes: Generalized dystonia HP:0007325

Show evidence (1 reference)

clinicaltrials:NCT00142259 SUPPORT Human Clinical

"The purpose of this study is to evaluate the efficacy and safety of bilateral deep brain stimulation of the internal globus pallidus for treating idiopathic generalized or severe segmental dystonia."

The registry record establishing the trial's identity, target population and intervention. The title is the registry's own German-language official title, copied verbatim from the cached record rather than translated or replaced with the English publication title - this is the same trial published in English as PMID:17093249, which is cited on the deep brain stimulation treatment under its own title.

🧫

Experimental Models

1

Patient-derived cholinergic motor neurons IPSC_DERIVED_MODEL

Cholinergic motor neurons generated from DYT1 patients, either by direct conversion of skin fibroblasts or by differentiation of induced pluripotent stem cells, carrying the patient heterozygous GAG deletion in human cells. This is the model that works where the heterozygous mouse does not, and it is also the model that disagrees with the mouse about what the nuclear lesion looks like. Isogenic controls - genomically corrected patient lines and engineered deletion in healthy lines - are available and were used in the RANBP17 work, which is what makes the transport findings attributable to the allele rather than to line background.

Organism

human NCBITaxon:9606

Publication

PMID:33468570

Pathograph links

Impaired Nucleocytoplasmic Transport recapitulates fidelity: moderate observes: cellular Measures impaired transport of both protein and mRNA cargo in human cells carrying the patient genotype, and identifies RANBP17 loss as its molecular correlate with a rescue experiment.

Limitations: Cultured neurons lack the striatal circuitry the disease is about, and the cell type studied is a cholinergic motor neuron rather than a striatal cholinergic interneuron, so the transport defect is demonstrated in a related but not identical vulnerable population.

Readouts

Nucleocytoplasmic transport of protein and mRNA cargo

Direction: DECREASED

Interpretation: The defining measurement of the node in human patient-derived cells.

Show evidence (1 reference)

PMID:33468570 SUPPORT In Vitro

"impaired nucleocytoplasmic transport (NCT) of mRNAs and proteins"

Reports the transport measurement in patient-derived neurons.

Transport activity after RANBP17 overexpression

Direction: RESTORED

Interpretation: The rescue that makes the transport defect causal for the developmental phenotype rather than merely correlated with it.

Show evidence (1 reference)

PMID:38438257 SUPPORT In Vitro

"the overexpression of RANBP17 emerged as a substantial mitigating factor, effectively restoring impaired NCT activity and rescuing neurodevelopmental deficits observed in DYT1 MNs"

Reports restoration of both the transport readout and the developmental phenotype.

Show evidence (1 reference)

PMID:38438257 SUPPORT In Vitro

"These patient-specific neurons retain the donor's heterozygous TOR1A mutation"

Establishes that the model carries the human disease genotype at the human zygosity, which is what makes it informative where the mouse is not.

Neuronal Nuclear Envelope Disruption partially recapitulates fidelity: moderate observes: cellular Reproduces nuclear envelope pathology - markedly thickened nuclear lamina, disrupted nuclear morphology, LMNB1 upregulation and mislocalization - but not the perinuclear blebs that are the signature lesion in the mouse models. It supports the node while contradicting the mouse's account of what the node looks like in human cells.

Limitations: The absence of blebs means the human and mouse evidence for this node are not interchangeable, and no patient brain tissue has confirmed either morphology in vivo. See the HUMAN_MODEL_MISMATCH discussion.

Readouts

Perinuclear blebs

Direction: UNCHANGED

Interpretation: A real negative result: the lesion that defines the mouse models is absent in human patient-derived neurons.

Show evidence (1 reference)

PMID:33468570 SUPPORT In Vitro

"whereas they lack the perinuclear "blebs" that are often observed in animal models"

Records the negative finding in full: the human patient-derived motor neurons lack the lesion that defines the mouse models.

Show evidence (1 reference)

PMID:33468570 SUPPORT In Vitro

"markedly thickened nuclear lamina, disrupted nuclear morphology"

Reports the envelope pathology that is present, which is what licenses PARTIALLY_RECAPITULATES rather than FAILS_TO_RECAPITULATE.

🐁

Animal Models

3

Tor1a heterozygous GAG-deletion knock-in mouse

The genotype-matched model: a mouse carrying one copy of the same in-frame GAG deletion patients carry. It is the model that ought to reproduce the disease and largely does not, which is the central translational problem in this field. It does reproduce a specific neurochemical defect - reduced evoked striatal dopamine release, correctable with trihexyphenidyl - so it is informative for that node while failing at the level of overt pathology and dystonia.

Species

Mouse

Genotype

Tor1a+/dGAG (heterozygous in-frame GAG deletion)

Publication

PMID:30707939

Pathograph links

Reduced Striatal Dopamine Release recapitulates fidelity: moderate observes: cellular Directly measures reduced evoked dopamine release in the striatum of a mouse carrying the human allele, by ex vivo fast-scan cyclic voltammetry and in vivo microdialysis.

Limitations: The corresponding human data are reduced striatal D2 receptor density and altered dopamine metabolites, not a direct measurement of evoked release, so the human and mouse readouts are related but not the same quantity.

Readouts

Evoked striatal dopamine release

Direction: DECREASED

Interpretation: The defining measurement of this node in the model system.

Show evidence (1 reference)

PMID:30707939 SUPPORT Model Organism

"we found that DA release was significantly reduced in Dyt1 knockin mice"

Reports the measured reduction in the knock-in genotype.

Dopamine release after trihexyphenidyl

Direction: RESTORED

Interpretation: The rescue arm, which is what ties the clinically preferred drug to this node.

Show evidence (1 reference)

PMID:30707939 SUPPORT Model Organism

"THP restored DA release in Dyt1 mice through a nAChR-dependent mechanism"

Reports restoration of the readout and the receptor dependence of the rescue.

Show evidence (1 reference)

PMID:30707939 SUPPORT Model Organism

"a significant reduction in striatal DA release is observed in several mouse models of DYT1 dystonia"

Establishes that the dopamine-release defect replicates across independent DYT1 mouse models, which is what makes this model informative for the node rather than a single-laboratory observation.

TorsinA-null and homozygous knock-in mouse neurons

The models in which the nuclear envelope lesion was discovered. Complete loss of torsinA, or homozygosity for the disease deletion, produces severely abnormal nuclear membranes specifically in neurons, with non-neuronal cells appearing normal - the observation that made nuclear envelope biology the dominant mechanistic account of this disease and that explains how a ubiquitously expressed gene causes a neurological illness.

Species

Mouse

Genotype

Tor1a-/- and Tor1a dGAG/dGAG

Publication

PMID:16364897

Pathograph links

Neuronal Nuclear Envelope Disruption recapitulates fidelity: moderate observes: cellular Demonstrates the nuclear envelope lesion and its neuron-selectivity, and establishes its developmental timing.

Limitations: The genotypes are homozygous null or homozygous deletion; patients are heterozygous, and heterozygous mice show no pathology. The specific morphology seen here - perinuclear blebs - is also not what patient-derived human neurons show, so the node is supported but its mouse morphology should not be assumed to transfer. Fidelity is MODERATE rather than HIGH for those two reasons together.

Readouts

Neuronal nuclear membrane morphology

Direction: ALTERED

Interpretation: The structural lesion defining the node, restricted to neurons.

Show evidence (1 reference)

PMID:16364897 SUPPORT Model Organism

"contain severely abnormal nuclear membranes, although non-neuronal cell types appear normal"

Reports the morphological measurement and its cell-type restriction.

Show evidence (1 reference)

PMID:16364897 SUPPORT Model Organism

"These observations demonstrate that neurons have a unique requirement for nuclear envelope localized torsinA function and suggest that loss of this activity is a key molecular event in the pathogenesis of DYT1 dystonia."

The authors' own statement that this model is informative for the pathogenesis of the human disease at this node.

Forebrain conditional torsinA knockout mouse

The model that produces an overt movement phenotype. Deleting torsinA in embryonic progenitors of forebrain cholinergic and GABAergic neurons causes dystonic-like twisting movements appearing during juvenile maturation, coinciding with selective loss of dorsal striatal large cholinergic interneurons. It is the strongest available link from torsinA loss to a dystonic phenotype, and the model that identified the vulnerable cell type.

Species

Mouse

Genotype

Conditional Tor1a deletion in embryonic forebrain cholinergic and GABAergic progenitors

Publication

PMID:26052670

Pathograph links

Striatal Cholinergic Interneuron Dysfunction recapitulates fidelity: moderate observes: cellular Identifies the selectively vulnerable cell type and characterizes the surviving population as morphologically, electrophysiologically and connectionally abnormal.

Limitations: Conditional homozygous deletion in a defined progenitor population is not the human genetic state, and the cell loss seen here is more severe than anything reported in patients, whose striatum shows cholinergic abnormalities without overt degeneration.

Readouts

Dorsal striatal large cholinergic interneuron number

Direction: DECREASED

Interpretation: The cellular lesion whose timing coincides with symptom onset in this model.

Show evidence (1 reference)

PMID:26052670 SUPPORT Model Organism

"The onset of these movements coincides with selective degeneration of dorsal striatal large cholinergic interneurons (LCI), and surviving LCI exhibit morphological, electrophysiological, and connectivity abnormalities."

Reports the cell loss and the abnormality of survivors.

Show evidence (1 reference)

PMID:26052670 SUPPORT Model Organism

"These findings demonstrate that dorsal LCI have a unique requirement for torsinA function during striatal maturation, and link abnormalities of these cells to dystonic-like movements in an overtly symptomatic animal model."

The authors' statement linking this cell type to the movement phenotype, which is what makes the model informative for this node.

Maturation-Dependent Disruption of Neuronal Development recapitulates fidelity: moderate observes: organism Shows that the phenotype is timed to juvenile CNS maturation rather than present from birth or acquired in adulthood, matching the childhood onset of the human disease.

Limitations: Mouse juvenile maturation and human childhood are matched only in ordinal terms; the model cannot speak to the specific age window or to why human onset clusters around 9 years.

Show evidence (1 reference)

PMID:26052670 SUPPORT Model Organism

"causes dystonic-like twisting movements that emerge during juvenile CNS maturation"

Establishes the maturation-dependent timing of the phenotype.

{ }

Source YAML

click to show

name: Early-onset Generalized Limb-onset Dystonia
creation_date: "2026-09-21T00:00:00Z"
category: Mendelian
synonyms:
- DYT1
- DYT1 dystonia
- DYT-TOR1A
- Oppenheim dystonia
- early-onset torsion dystonia
- early-onset generalized torsion dystonia
- early-onset primary dystonia
- dystonia musculorum deformans
- torsion dystonia type 1
- EOTD
description: >-
  The most common inherited early-onset generalized dystonia, caused by a single
  recurrent in-frame three-base-pair deletion in TOR1A that removes one glutamate
  from a conserved region of torsinA, an AAA+ ATPase of the endoplasmic reticulum
  lumen and perinuclear space. More than 98% of affected individuals carry the
  identical c.907_909delGAG allele, so unlike most Mendelian diseases this entry
  describes essentially one variant rather than a spectrum.

  Clinically it is an isolated dystonia in the Albanese sense: dystonia is the
  only motor feature. Onset is in childhood, typically in a limb, usually as an
  action-specific disturbance of gait or as writer's cramp; over months to years
  the movements lose their action specificity and spread to other limbs and the
  trunk. Cervical and bulbar segments are relatively spared, which distinguishes
  it from DYT6/THAP1 dystonia. Cognition is not affected, life span is not known
  to be shortened, and there is no overt neuropathological signature - this is a
  disorder of how a structurally intact motor system functions and matures, not a
  degeneration. The entry is built around that distinction.

  Two features dominate the genetics. Penetrance is approximately 30%, so roughly
  seven in ten carriers never develop dystonia, and an unaffected parent cannot be
  assumed to be a non-carrier. And in the Ashkenazi Jewish population the great
  majority of cases descend from a single founder mutation roughly 350 years old,
  which is why carrier frequency there is far higher than the disease is common.

  The mechanistic chain is unusually well characterised at its molecular end and
  openly incomplete at its clinical end, and this entry is written to show that
  asymmetry rather than to smooth it over. TorsinA's ATPase activity requires the
  cofactors LAP1 and LULL1; the deletion impairs that cycle, and torsin-deficient
  neurons develop abnormal nuclear envelopes and impaired nucleocytoplasmic
  transport. Downstream, dorsal striatal cholinergic interneurons are selectively
  vulnerable in conditional mouse mutants, striatal dopamine release is reduced in
  knock-in mice, and human imaging shows reduced striatal D2 availability together
  with an abnormal cerebellothalamocortical pathway. What is not established is
  the step from any of these to the dystonic movement itself.

  The nuclear-envelope arm carries a specific and instructive species caveat,
  recorded here structurally rather than as prose. Perinuclear "blebs" are the
  signature lesion in torsinA-null and knock-in mice, but patient-derived
  cholinergic motor neurons carrying the same heterozygous deletion do not show
  them - they show a thickened nuclear lamina, LMNB1 dysregulation and impaired
  transport instead. Heterozygous animals also fail to develop pathology at all.
  Those are logged as a HUMAN_MODEL_MISMATCH discussion and as fidelity-qualified
  model links, not as a footnote.

  Treatment is symptomatic and effective. Bilateral deep brain stimulation of the
  internal globus pallidus is the defining intervention, is supported by a
  sham-controlled randomized trial in generalized and segmental dystonia, and
  produces large sustained improvements in DYT1 specifically; shorter disease
  duration predicts better outcome, which is the argument for early referral. Oral
  trihexyphenidyl is the preferred small-molecule agent and is dose-limited by
  antimuscarinic side effects.

  Relationship to neighbouring entries: Torsion_Dystonia_6 is the THAP1 disease
  whose transcription factor represses the TOR1A promoter, so the two entries meet
  at that gene from opposite directions; Cervical_Dystonia covers common
  adult-onset sporadic focal disease and deliberately binds no causal gene;
  KMT2B-Related_Dystonia is the other major childhood-onset generalized monogenic
  dystonia but is a complex rather than isolated dystonia. No pathophysiology node
  declares conforms_to: kb/modules/ was searched and no module covers nuclear
  envelope dysfunction or basal ganglia motor circuit dysfunction.
disease_term:
  preferred_term: DYT1 early-onset generalized limb-onset dystonia
  term:
    id: MONDO:0007492
    label: early-onset generalized limb-onset dystonia
parents:
- dystonic disorder
- movement disorder
- autosomal dominant disease
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
    notes: >-
      An isolated movement disorder presenting to and managed by neurology; the
      clinical chapter covering it is the dystonia chapter.
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    notes: >-
      A monogenic autosomal dominant disease whose counselling problem - a single
      recurrent allele with roughly 30% penetrance - is a genetics problem rather
      than a movement-disorder one.
prevalence:
- population: Ashkenazi Jewish population
  measure_type: CARRIER_FREQUENCY
  prevalence_class: BAND_1_5_PER_10000
  rate_low: 16.7
  rate_high: 50.0
  notes: >-
    A frequency of the founder GAG-deletion mutation, not disease prevalence. The
    reported 1/6,000 to 1/2,000 range converts to 16.7-50 per 100,000; no
    synthetic midpoint is assigned. Because penetrance is approximately 30%, the
    frequency of manifesting disease in this population is substantially lower
    than this figure, but the cited source does not report a manifesting rate and
    none is derived here.

    What measure_type should be is not fully resolved by the source, and the
    record is deliberately not written as though it were. The quoted sentence
    says only that "this dominant mutation" has a "current high frequency", and
    its closing clause speaks of "disease allele frequencies" - so whether
    1/6,000-1/2,000 is a heterozygote (carrier) frequency or an allele frequency
    is left open, and the two differ by a factor of about two. CARRIER_FREQUENCY
    is recorded because PrevalenceMeasureEnum has no allele-frequency value
    (permissible values checked: POINT_PREVALENCE, BIRTH_PREVALENCE,
    LIFETIME_PREVALENCE, PERIOD_PREVALENCE, ANNUAL_INCIDENCE, CARRIER_FREQUENCY,
    CASES_IN_LITERATURE, UNKNOWN) and because for a heterozygous dominant allele
    the carriers are the heterozygotes the enum's own definition names. Treat the
    band as the magnitude the source supports, not as a resolved carrier rate.
  evidence:
  - reference: PMID:7719342
    reference_title: "Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "its current high frequency (between 1/6,000 and 1/2,000)"
    explanation: >-
      Supplies the carrier-frequency range for the founder allele in the
      Ashkenazi Jewish population.
- population: Ashkenazi Jewish early-onset cases
  measure_type: UNKNOWN
  prevalence_class: NOT_YET_DOCUMENTED
  notes: >-
    Not an occurrence rate but the founder share: more than 90% of early-onset
    idiopathic torsion dystonia in this population traces to one mutation that
    arose about 350 years ago. Recorded as a prevalence record because it governs
    how the carrier frequency above should be read, and marked UNKNOWN /
    NOT_YET_DOCUMENTED rather than converted into a rate it does not supply.
  evidence:
  - reference: PMID:7719342
    reference_title: "Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our data show that the vast majority (> 90%) of early-onset ITD cases in the Ashkenazi population are due to a single founder mutation, which we estimate first appeared approximately 350 years ago."
    explanation: >-
      Establishes the single-founder origin and its age, which is why carrier
      frequency in this population is high relative to the disease's rarity.
inheritance:
- name: Autosomal dominant with reduced penetrance
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  penetrance: INCOMPLETE
  expressivity: VARIABLE
  description: >-
    Autosomal dominant transmission of a single recurrent TOR1A allele. Each child
    of an affected individual has a 50% chance of inheriting the variant, but only
    about 30% of those who inherit it ever develop dystonia. Reduced penetrance is
    the central counselling fact of this disease, not a caveat on it: most carriers
    in a pedigree are clinically normal, so an unaffected parent or sibling cannot
    be assumed to be a non-carrier, and apparently sporadic cases are frequently
    inherited. Expressivity among those who do manifest is also variable, so an
    affected child may be more or less severely affected than the transmitting
    parent.
  evidence:
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "DYT-TOR1A is inherited in an autosomal dominant manner."
    explanation: GeneReviews states the mode of inheritance.
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The penetrance for the TOR1A c.907_909delGAG deletion is approximately 30%; thus, on average, 30% of individuals who inherit the TOR1A c.907_909delGAG deletion develop dystonia and 70% do not develop dystonia."
    explanation: >-
      Quantifies penetrance directly and states the complementary 70%
      non-manifesting fraction, which is the fact that governs counselling.
  - reference: PMID:23649720
    reference_title: "Phenomenology and classification of dystonia: a consensus update."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    snippet: "DYT1 dystonia is transmitted as an autosomal-dominant trait with a penetrance of about 30%."
    explanation: >-
      Independent corroboration of the penetrance figure from the international
      classification consensus, cited here because a single-source penetrance
      claim is exactly the kind that should be checked against a second authority.
      Graded OTHER because the publication is an expert consensus statement rather
      than a study reporting data, and INDIRECT because the sentence restates
      established literature rather than measuring penetrance.
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "DYT-TOR1A is associated with significant intrafamilial variability; thus, dystonia in an affected individual may be more or less severe than that of the parent from whom the TOR1A pathogenic variant was inherited."
    explanation: Supports the VARIABLE expressivity value alongside incomplete penetrance.
pathophysiology:
- name: Heterozygous TOR1A GAG Deletion
  biological_scale: MOLECULAR
  description: >-
    A heterozygous in-frame three-base-pair deletion, c.907_909delGAG, in exon 5 of
    TOR1A. It removes one of a pair of glutamate residues from a conserved
    C-terminal region of torsinA without shifting the reading frame, so a
    near-full-length protein is made. More than 98% of affected individuals carry
    this same allele, which is unusual for a Mendelian disease and is why the
    entry can describe one variant rather than a spectrum.
  genetic_context:
    variant_origin: GERMLINE
    allele_type: DELETION
    zygosity: HETEROZYGOUS
    functional_impact_category: LOSS_OF_FUNCTION
  genes:
  - preferred_term: TOR1A
    term:
      id: hgnc:3098
      label: TOR1A
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  molecular_functions:
  - preferred_term: cofactor-dependent torsinA ATP hydrolysis
    modifier: DECREASED
    term:
      id: GO:0016887
      label: ATP hydrolysis activity
  downstream:
  - target: Impaired TorsinA AAA+ ATPase Function
    description: >-
      Deletion of the glutamate within the conserved region compromises the
      nucleotide-dependent cycle of the AAA+ domain, which is the proximate
      molecular consequence of the allele.
  evidence:
  - reference: PMID:9288096
    reference_title: "The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This deletion results in loss of one of a pair of glutamic-acid residues in a conserved region of a novel ATP-binding protein, termed torsinA."
    explanation: >-
      The original gene-identification paper states the molecular nature of the
      lesion - single glutamate loss from a conserved region of an ATP-binding
      protein - which is the definition of this node.
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "More than 98% of affected individuals have the 3-bp deletion c.907_909delGAG involving the highly conserved GAGGAG sequence in exon 5."
    explanation: >-
      Supplies the precise coding change and establishes that essentially the
      whole disease is attributable to this one allele.
  - reference: PMID:33468570
    reference_title: "Disease Modeling with Human Neurons Reveals LMNB1 Dysregulation Underlying DYT1 Dystonia."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "It is caused by a heterozygous mutation in Torsin A (TOR1A), a gene encoding a membrane-embedded ATPase."
    explanation: >-
      Supports the molecular-function binding on this node by naming what the
      gene disrupted here encodes: the disease-causing allele is a heterozygous
      TOR1A mutation, and TOR1A's product is an ATPase, so ATP hydrolysis is the
      activity the deletion acts on. INDIRECT because the sentence asserts the
      gene-to-activity link rather than the reduction itself, which the
      conserved-region glutamate loss above and the cofactor-cycle evidence on
      the next node carry. Graded HUMAN_CLINICAL because the quoted sentence
      states the human genetic aetiology, with quote_role BACKGROUND because it
      is this in-vitro paper's framing of established genetics rather than its
      own result.
- name: Impaired TorsinA AAA+ ATPase Function
  biological_scale: MOLECULAR
  description: >-
    TorsinA is an AAA+ ATPase resident in the endoplasmic reticulum lumen and the
    contiguous perinuclear space. Unlike most AAA+ proteins it lacks a complete
    catalytic site of its own and depends on the membrane cofactors LAP1 (nuclear
    envelope) and LULL1 (bulk ER), each of which supplies an arginine finger to
    complete the active site and trigger hydrolysis. The disease deletion sits in
    the region that mediates this regulated cycle, so the mutant protein is
    impaired in the cofactor-driven ATPase activity through which torsinA does its
    work. The functional readout that matters is not the catalytic rate in
    isolation but the ability to rescue nuclear envelope defects in
    torsin-deficient cells.
  molecular_functions:
  - preferred_term: cofactor-dependent torsinA ATP hydrolysis
    modifier: DECREASED
    term:
      id: GO:0016887
      label: ATP hydrolysis activity
  downstream:
  - target: Neuronal Nuclear Envelope Disruption
    description: >-
      Loss of regulated torsinA ATPase activity at the nuclear envelope removes
      the activity whose absence produces the membrane lesion in the next node.
  evidence:
  - reference: PMID:28814508
    reference_title: "Dynamic functional assembly of the Torsin AAA+ ATPase and its modulation by LAP1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "TorsinA is an essential AAA+ ATPase requiring LAP1 or LULL1 as cofactors."
    explanation: >-
      Establishes the enzyme class and the obligate cofactor dependence that
      defines how torsinA activity is regulated.
  - reference: PMID:28814508
    reference_title: "Dynamic functional assembly of the Torsin AAA+ ATPase and its modulation by LAP1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Engagement of the oligomer by LAP1 triggers ATP hydrolysis and rapid complex disassembly."
    explanation: >-
      Describes the cofactor-triggered hydrolysis step, supporting the
      characterization of torsinA function as a regulated ATPase cycle rather than
      constitutive catalysis.
  - reference: PMID:28814508
    reference_title: "Dynamic functional assembly of the Torsin AAA+ ATPase and its modulation by LAP1."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: IN_VITRO
    snippet: "These Torsin mutants are severely compromised in their ability to rescue nuclear envelope defects in Torsin-deficient cells, suggesting that TorsinA homo-oligomers play a key role in vivo."
    explanation: >-
      Links loss of correct torsin assembly to failure of nuclear envelope
      maintenance, which is the edge this node asserts. INDIRECT because the
      mutants studied are engineered oligomerization-interface variants rather
      than the disease GAG deletion, so the inference to the patient allele is a
      step removed.
- name: Neuronal Nuclear Envelope Disruption
  biological_scale: CELLULAR
  description: >-
    Loss of torsinA function produces abnormal nuclear envelope architecture that
    is, strikingly, restricted to neurons even though TOR1A is widely expressed -
    the classic statement of the tissue-specificity problem in this disease. In
    mouse null and homozygous knock-in neurons the lesion takes the form of
    perinuclear membrane blebs or herniations. In human patient-derived cholinergic
    motor neurons carrying the heterozygous deletion the lesion instead appears as
    a markedly thickened nuclear lamina with disrupted nuclear morphology and
    LMNB1 dysregulation, without the blebs. Both are nuclear envelope pathology;
    they are not the same lesion, and the entry does not treat the mouse
    morphology as established in humans. See the HUMAN_MODEL_MISMATCH discussion.
  biological_processes:
  - preferred_term: nuclear envelope organization
    modifier: DECREASED
    term:
      id: GO:0006998
      label: nuclear envelope organization
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Impaired Nucleocytoplasmic Transport
    description: >-
      A disordered nuclear envelope and lamina compromise the interface across
      which all nuclear import and export occurs.
  - target: Maturation-Dependent Disruption of Neuronal Development
    description: >-
      The envelope lesion arises in postmigratory embryonic neurons and worsens
      with maturation, tying the cellular defect to a developmental window rather
      than to ongoing adult injury.
  evidence:
  - reference: PMID:16364897
    reference_title: "Loss of the dystonia-associated protein torsinA selectively disrupts the neuronal nuclear envelope."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "contain severely abnormal nuclear membranes, although non-neuronal cell types appear normal"
    explanation: >-
      Establishes both the nuclear membrane lesion and its neuron-selectivity in
      torsinA-null and knock-in mice, which is the core claim of this node.
  - reference: PMID:16364897
    reference_title: "Loss of the dystonia-associated protein torsinA selectively disrupts the neuronal nuclear envelope."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These observations demonstrate that neurons have a unique requirement for nuclear envelope localized torsinA function and suggest that loss of this activity is a key molecular event in the pathogenesis of DYT1 dystonia."
    explanation: >-
      States the authors' inference that nuclear-envelope-localized torsinA
      function is the relevant activity, supporting placement of this node on the
      main causal chain.
  - reference: PMID:33468570
    reference_title: "Disease Modeling with Human Neurons Reveals LMNB1 Dysregulation Underlying DYT1 Dystonia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "markedly thickened nuclear lamina, disrupted nuclear morphology"
    explanation: >-
      Supplies the human counterpart of the envelope lesion in patient-derived
      motor neurons carrying the heterozygous deletion, which is what licenses
      this node for the human disease rather than only for mouse models.
  - reference: PMID:33468570
    reference_title: "Disease Modeling with Human Neurons Reveals LMNB1 Dysregulation Underlying DYT1 Dystonia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "we uncover that the nuclear lamina protein LMNB1 is upregulated in DYT1 cells and exhibits abnormal subcellular distribution in a cholinergic MNs-specific manner"
    explanation: >-
      Identifies the specific lamina protein whose dysregulation accompanies the
      human envelope lesion, and records that it is cell-type-restricted.
- name: Impaired Nucleocytoplasmic Transport
  biological_scale: CELLULAR
  description: >-
    Patient-derived DYT1 motor neurons show impaired bidirectional traffic across
    the nuclear envelope, affecting both protein import and export and the export
    of mRNA. A specific molecular correlate has been identified: RANBP17, an
    importin-beta superfamily nuclear transport receptor, is strongly
    downregulated in DYT1 motor neurons, and restoring it rescues both the
    transport defect and the neurodevelopmental phenotype. That rescue is what
    makes this node causal rather than merely correlated, and it places impaired
    transport upstream of the developmental abnormality rather than beside it.
  biological_processes:
  - preferred_term: nucleocytoplasmic transport
    modifier: DECREASED
    term:
      id: GO:0006913
      label: nucleocytoplasmic transport
  - preferred_term: protein import into the nucleus in DYT1 motor neurons
    modifier: DECREASED
    term:
      id: GO:0006606
      label: protein import into nucleus
  - preferred_term: mRNA export from the nucleus in DYT1 motor neurons
    modifier: DECREASED
    term:
      id: GO:0006406
      label: mRNA export from nucleus
  cell_types:
  - preferred_term: patient-derived cholinergic motor neuron
    term:
      id: CL:0000100
      label: motor neuron
  downstream:
  - target: Maturation-Dependent Disruption of Neuronal Development
    description: >-
      Restoring nucleocytoplasmic transport by RANBP17 overexpression rescues the
      neurodevelopmental deficits of DYT1 motor neurons, which is direct evidence
      that the transport defect is upstream of the developmental one.
  evidence:
  - reference: PMID:33468570
    reference_title: "Disease Modeling with Human Neurons Reveals LMNB1 Dysregulation Underlying DYT1 Dystonia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "impaired nucleocytoplasmic transport (NCT) of mRNAs and proteins"
    explanation: >-
      Establishes the transport defect in human patient-derived neurons and that
      it affects both cargo classes.
  - reference: PMID:38438257
    reference_title: "RANBP17 Overexpression Restores Nucleocytoplasmic Transport and Ameliorates Neurodevelopment in Induced DYT1 Dystonia Motor Neurons."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "we identified that the expression level of RANBP17, a RAN-binding protein crucial for NCT regulation, exhibited a significant reduction in DYT1 MNs"
    explanation: >-
      Identifies the specific transport receptor whose loss accompanies the
      defect, giving the node a molecular handle rather than a phenomenological
      one.
  - reference: PMID:38438257
    reference_title: "RANBP17 Overexpression Restores Nucleocytoplasmic Transport and Ameliorates Neurodevelopment in Induced DYT1 Dystonia Motor Neurons."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "the overexpression of RANBP17 emerged as a substantial mitigating factor, effectively restoring impaired NCT activity and rescuing neurodevelopmental deficits observed in DYT1 MNs"
    explanation: >-
      A rescue experiment, which is the strongest available support for the
      downstream edge to the developmental node: correcting transport corrects
      development.
- name: Maturation-Dependent Disruption of Neuronal Development
  biological_scale: CELLULAR
  description: >-
    The consequences of torsinA loss are tied to a developmental window rather
    than to progressive adult injury. Nuclear envelope abnormalities appear in
    postmigratory embryonic neurons and worsen as those neurons mature; in
    conditional mouse mutants dystonic movements emerge during juvenile CNS
    maturation; and patient-derived motor neurons show reduced neurite length and
    branching. This node is why the disease is described as functional and
    developmental rather than degenerative, and it is the mechanistic counterpart
    of the clinical observation that symptoms begin in childhood, spread over a few
    years, and then persist without shortening life span.
  biological_processes:
  - preferred_term: neuron projection development
    modifier: DECREASED
    term:
      id: GO:0031175
      label: neuron projection development
  cell_types:
  - preferred_term: developing neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Striatal Cholinergic Interneuron Dysfunction
    description: >-
      The maturing dorsal striatum is where the developmental requirement for
      torsinA is most stringent, and its cholinergic interneurons are the cell
      type that fails.
  evidence:
  - reference: PMID:16364897
    reference_title: "Loss of the dystonia-associated protein torsinA selectively disrupts the neuronal nuclear envelope."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These membrane abnormalities develop in postmigratory embryonic neurons and subsequently worsen with further neuronal maturation, a finding evocative of the developmental dependence of DYT1 dystonia."
    explanation: >-
      States the developmental timing of the cellular lesion and explicitly ties
      it to the developmental dependence of the human disease.
  - reference: PMID:26052670
    reference_title: "Forebrain deletion of the dystonia protein torsinA causes dystonic-like movements and loss of striatal cholinergic neurons."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "causes dystonic-like twisting movements that emerge during juvenile CNS maturation"
    explanation: >-
      Shows the behavioural phenotype itself is maturation-timed rather than
      present from birth or acquired in adulthood.
  - reference: PMID:33468570
    reference_title: "Disease Modeling with Human Neurons Reveals LMNB1 Dysregulation Underlying DYT1 Dystonia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "show reduced neurite length and branches"
    explanation: >-
      Supplies the human cellular neurodevelopmental readout that the RANBP17
      rescue experiment later corrects.
- name: Striatal Cholinergic Interneuron Dysfunction
  biological_scale: CELLULAR
  description: >-
    Dorsal striatal large cholinergic interneurons have a distinctive requirement
    for torsinA during striatal maturation. In mice with conditional forebrain
    deletion, the emergence of dystonic movements coincides with selective loss of
    these cells, and the survivors are morphologically, electrophysiologically and
    connectionally abnormal. Cholinergic abnormalities are also present in
    postmortem striatum from DYT1 patients, which is the main piece of human
    tissue evidence anywhere in this chain. Note the terminological hazard: the
    mouse model shows selective degeneration of this one interneuron class, which
    is not the same as the disease being a neurodegeneration - the human disorder
    has no overt neuropathological signature.
  cell_types:
  - preferred_term: dorsal striatal large cholinergic interneuron
    term:
      id: CL:0020007
      label: dorso-striatal cholinergic-GABAergic neuron
  biological_processes:
  - preferred_term: striatal cholinergic synaptic transmission
    modifier: ABNORMAL
    term:
      id: GO:0007271
      label: synaptic transmission, cholinergic
  locations:
  - preferred_term: dorsal striatum
    term:
      id: UBERON:0002435
      label: striatum
  downstream:
  - target: Reduced Striatal Dopamine Release
    description: >-
      Acetylcholine released by striatal cholinergic interneurons drives dopamine
      release from nigrostriatal terminals through nicotinic receptors, so
      cholinergic interneuron dysfunction propagates directly into the dopaminergic
      readout.
  - target: Basal Ganglia and Cerebellothalamocortical Network Dysfunction
    description: >-
      Cholinergic interneurons are the principal local modulator of striatal
      output, so their dysfunction alters basal ganglia network signalling
      independently of the dopaminergic arm.
  evidence:
  - reference: PMID:26052670
    reference_title: "Forebrain deletion of the dystonia protein torsinA causes dystonic-like movements and loss of striatal cholinergic neurons."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The onset of these movements coincides with selective degeneration of dorsal striatal large cholinergic interneurons (LCI), and surviving LCI exhibit morphological, electrophysiological, and connectivity abnormalities."
    explanation: >-
      Establishes both the selective vulnerability of this cell type and that the
      surviving population is functionally abnormal, which is the substance of
      this node.
  - reference: PMID:26052670
    reference_title: "Forebrain deletion of the dystonia protein torsinA causes dystonic-like movements and loss of striatal cholinergic neurons."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we identify cholinergic abnormalities in postmortem striatal tissue from DYT1 dystonia patients"
    explanation: >-
      Human postmortem corroboration that the cholinergic abnormality is not a
      mouse-only finding. Graded HUMAN_CLINICAL because this specific claim rests
      on patient tissue, whereas the same paper's mouse results are graded
      MODEL_ORGANISM; the paper mixes sources and the items are split accordingly.
  - reference: PMID:26052670
    reference_title: "Forebrain deletion of the dystonia protein torsinA causes dystonic-like movements and loss of striatal cholinergic neurons."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "murine dystonic-like movements are reduced significantly with an antimuscarinic agent used clinically"
    explanation: >-
      Pharmacological validation of the cholinergic node: blocking muscarinic
      signalling reduces the movements, which is also the mechanistic rationale
      for trihexyphenidyl in patients.
- name: Reduced Striatal Dopamine Release
  biological_scale: CELLULAR
  description: >-
    Striatal dopamine signalling is abnormal in both directions of evidence.
    Knock-in mice carrying the heterozygous deletion show significantly reduced
    evoked dopamine release, and DYT1 patients show reduced striatal D2 receptor
    availability. The link to the cholinergic node above is mechanistic rather
    than merely associative: trihexyphenidyl restores dopamine release in Dyt1
    mice through a nicotinic-receptor-dependent route, which is the clearest
    account available of how the clinically preferred drug works. Levodopa, by
    contrast, does not increase dopamine release in these mice, matching the
    clinical observation that DYT1 dystonia is not dopa-responsive.
  cell_types:
  - preferred_term: nigrostriatal dopaminergic neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: striatal dopamine secretion
    modifier: DECREASED
    term:
      id: GO:0014046
      label: dopamine secretion
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  downstream:
  - target: Basal Ganglia and Cerebellothalamocortical Network Dysfunction
    description: >-
      Reduced dopaminergic drive and reduced D2 receptor availability alter the
      balance of striatal output pathways, feeding the network abnormality seen on
      imaging.
  evidence:
  - reference: PMID:30707939
    reference_title: "Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "we found that DA release was significantly reduced in Dyt1 knockin mice"
    explanation: >-
      Direct measurement of the reduced dopamine release that defines this node,
      in the mouse carrying the disease allele.
  - reference: PMID:30707939
    reference_title: "Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "Previous studies have demonstrated reductions in striatal D2 receptor density and abnormalities in DA metabolites in DYT1 patients."
    explanation: >-
      Records the human counterpart of the mouse finding. INDIRECT because the
      sentence is this paper's summary of prior patient literature rather than a
      result it measures; the paper's own data are rodent, which is why the item
      is graded MODEL_ORGANISM.
  - reference: PMID:30707939
    reference_title: "Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "THP restored DA release in Dyt1 mice through a nAChR-dependent mechanism"
    explanation: >-
      Establishes the cholinergic-to-dopaminergic mechanistic link asserted by the
      upstream edge, and supplies the mechanism of action for trihexyphenidyl.
  - reference: PMID:30707939
    reference_title: "Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    snippet: "In contrast, ʟ-DOPA, which is not usually effective for the treatment of DYT1 dystonia, did not increase dopamine release in either Dyt1 or control mice."
    explanation: >-
      Sources the levodopa half of this node's description, which was previously
      asserted without a citation. It is the pharmacological discriminator that
      separates this disease from dopa-responsive dystonia: the dopaminergic
      deficit here is in activity-dependent release rather than in dopamine
      synthesis or content, so supplying precursor does not correct it. The
      snippet reproduces the source's small-capital letter in "ʟ-DOPA" verbatim.
- name: Basal Ganglia and Cerebellothalamocortical Network Dysfunction
  biological_scale: TISSUE
  description: >-
    The convergence point, and the least mechanistically closed node in the entry.
    Functional imaging in DYT1 carriers shows reduced striatal GABA and dopamine
    receptor availability, increased metabolic activity in the lentiform nucleus,
    supplementary motor area and cerebellum, and an abnormal cerebellothalamocortical
    pathway. Notably these changes are present in carriers irrespective of whether
    they manifest dystonia, so network abnormality alone is not sufficient for
    disease - what distinguishes manifesting from non-manifesting carriers appears
    to involve the distal thalamocortical segment and compensatory putaminal
    changes. That is the imaging-level correlate of 30% penetrance. What remains
    unestablished is the causal step from this network state to the dystonic
    movement itself; the entry asserts the association and stops there.
  locations:
  - preferred_term: globus pallidus
    term:
      id: UBERON:0001875
      label: globus pallidus
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  downstream:
  - target: Limb-onset dystonia
    description: >-
      Abnormal motor network output is the presumed proximate cause of the
      dystonic postures and movements. This edge is the weakest in the chain and
      is supported by association and by the therapeutic response to pallidal
      stimulation rather than by a demonstrated causal path.
  evidence:
  - reference: PMID:37165749
    reference_title: "Neuroimaging findings in DYT1 dystonia and the pathophysiological implication: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All DYT1 gene carriers irrespective of clinical penetrance have reduced striatal GABA, dopamine receptors and increased metabolic activity in the lentiform nucleus, supplementary motor area, and cerebellum in addition to an abnormal cerebellothalamocortical pathway."
    explanation: >-
      The systematic review's primary result, establishing both the network
      abnormality and the critical observation that it is present in
      non-manifesting carriers too.
  - reference: PMID:37165749
    reference_title: "Neuroimaging findings in DYT1 dystonia and the pathophysiological implication: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we propose that DYT1 dystonia is a cerebellostriatothalamocortical network disorder affecting either the structure or function of the different structures or nodes in the network"
    explanation: >-
      States the review's synthesis, which is the framing this node adopts - a
      distributed network disorder rather than a single-structure lesion.
  - reference: PMID:26052670
    reference_title: "Forebrain deletion of the dystonia protein torsinA causes dystonic-like movements and loss of striatal cholinergic neurons."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "primary dystonia results from abnormal functioning of a structurally intact central nervous system"
    explanation: >-
      Supports the characterization of the network state as functional rather than
      structural-degenerative, which is the distinction this entry is built
      around. INDIRECT because the sentence states the field's accepted framing in
      the paper's introduction rather than reporting a measurement.
phenotypes:
- category: Neurologic
  name: Limb-onset dystonia
  description: >-
    The presenting feature and the one the disease is named for. Dystonia begins
    in a leg or an arm, with a median onset age of 9 years. It is initially
    action-specific - an abnormal gait with foot inversion or knee flexion, or a
    hand posture that appears only on writing - and becomes present at rest as it
    progresses. Onset in axial, cervical or cranial regions occurs but is much
    less common, which is the clinical signature separating this entity from
    DYT6/THAP1 dystonia. Pain is not prominent.

    Onset is childhood in the great majority, but not exclusively: about 5% of
    affected individuals present after age 30. That tail matters clinically
    because "early-onset" in the entity's own name invites a late presentation
    being read as excluding the diagnosis, and it matters for counselling,
    because an at-risk relative who is well in their twenties is not thereby
    past risk.
  phenotype_term:
    preferred_term: Limb-onset dystonia
    term:
      id: HP:0002451
      label: Limb dystonia
    onset:
      onset_category: CHILDHOOD
      notes: >-
        Median age of onset 9 years, interquartile range 7-12 years, with about
        5% of individuals presenting after age 30. Only onset_category is set:
        the source reports a median and an interquartile range, and putting 9
        into mean_age_years or 7/12 into min_age_years/max_age_years would
        relabel a median as a mean and quartile bounds as extremes. The numbers
        are kept here verbatim instead, and both are carried by their own
        evidence items on this phenotype.
  sequelae:
  - target: Generalized dystonia
    description: >-
      Limb-onset dystonia spreads over months to years to other limbs and the
      trunk, particularly when onset was in a leg.
  evidence:
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dystonia typically begins in a leg or arm. While onset can occur in axial, cervical, or cranial regions, these are far less common than onset in a limb."
    explanation: >-
      States the limb-onset pattern and that non-limb onset is much less common,
      which is the defining clinical fact of this entity.
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "DYT1-TOR1A is an isolated dystonia with onset typically in childhood (median age of onset: 9 years; interquartile range: 7-12 years)."
    explanation: >-
      Supplies the onset age distribution and records that the dystonia is
      isolated rather than part of a complex syndrome.
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "About 5% of individuals have onset after age 30 years."
    explanation: >-
      Quantifies the adult-onset minority, which bounds how far the entity's
      "early-onset" name can be relied on diagnostically. REVIEW_SYNTHESIS
      because GeneReviews is summarising the published cohorts rather than
      reporting its own series; evidence_source stays HUMAN_CLINICAL because the
      figure describes human patients.
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Initially, dystonia is typically triggered by specific actions, presenting as a change in gait (e.g., foot inversion or abnormal flexion of the knee or hip) or as writer's cramp"
    explanation: >-
      Describes the action-specific character of the earliest signs, which is why
      the presentation is often mistaken for an orthopaedic or functional problem.
  - reference: PMID:33488508
    reference_title: "Pallidal Deep Brain Stimulation for Monogenic Dystonia: The Effect of Gene on Outcome."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    quote_role: BACKGROUND
    snippet: "typically begins between 9 and 12 years in a limb then spreads to become generalized with relative sparing of cervical and bulbar segments"
    explanation: >-
      Independent statement of the onset region and the relative cervical/bulbar
      sparing that distinguishes this entity from DYT6. Graded OTHER because the
      publication is a narrative review of DBS outcomes, and marked BACKGROUND
      because this sentence sets up the clinical entity rather than reporting the
      review's own analysis.
- category: Neurologic
  name: Generalized dystonia
  description: >-
    The characteristic endpoint in most affected individuals: dystonic movements
    lose their action specificity, appear at rest, and spread from the originally
    affected limb to other limbs and the trunk over months to years. Progression
    is particularly common when onset was in a leg. Once established, dystonic
    movements usually persist for life.
  phenotype_term:
    preferred_term: Generalized dystonia
    term:
      id: HP:0007325
      label: Generalized dystonia
    clinical_course: PROGRESSIVE
  sequelae:
  - target: Joint contracture
    description: >-
      Sustained dystonic posturing holds joints outside their normal range for
      long periods, so fixed contracture develops as a secondary musculoskeletal
      consequence of the movement disorder rather than as a feature of it.
      GeneReviews names joint contracture among the long-term orthopedic
      complications that timely treatment is meant to prevent.
  - target: Kyphoscoliosis
    description: >-
      Axial and truncal dystonia imposes asymmetric sustained load on the growing
      spine, so spinal deformity follows in a proportion of patients. This edge is
      why the entry treats early referral as more than a comfort argument: the
      deformity, once fixed, is not reversed by later stimulation.
  - target: Hip dislocation
    description: >-
      Dystonic posturing at the hip during skeletal growth can displace the joint,
      the third of the secondary orthopedic complications GeneReviews names as a
      target of physiatry and physical therapy.
  evidence:
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dystonia can also spread to other body regions, progressing over months to years to \"generalized dystonia\" involving other limbs and the trunk. In individuals with onset in a leg, progression of dystonia is common."
    explanation: >-
      States the generalization process, its time course, and that leg onset
      predicts it - the basis for the PROGRESSIVE clinical course.
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Once dystonic movements appear, they usually persist lifelong."
    explanation: >-
      Establishes persistence, which together with the absence of degeneration
      characterizes the disease as a stable acquired motor disability rather than
      a progressive neurological decline.
- category: Neurologic
  name: Writer's cramp
  description: >-
    Task-specific upper-limb dystonia presenting as tightening or abnormal
    posturing of the hand and arm during writing. It is one of the two
    characteristic presenting forms, and is also the form in which disease most
    often remains restricted when it does not generalize.
  phenotype_term:
    preferred_term: Writer's cramp
    term:
      id: HP:0002356
      label: Writer's cramp
  evidence:
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "writer's cramp, characterized by tightening and/or posturing of the hand or arm with writing"
    explanation: Describes the task-specific upper-limb presentation.
- category: Neurologic
  name: Persistent focal dystonia
  description: >-
    Not every carrier who manifests generalizes. In about one in five affected
    individuals the dystonia stays confined to a single body region, most often as
    writer's cramp. This is a distinct outcome from non-penetrance: these
    individuals do have dystonia, it simply does not spread.
  phenotype_term:
    preferred_term: Focal dystonia
    term:
      id: HP:0004373
      label: Focal dystonia
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In approximately 20% of individuals dystonia remains restricted to a single body region, most often as writer's cramp."
    explanation: >-
      Supplies both the phenotype and the ~20% figure, which is the basis for the
      OCCASIONAL (5-29%) frequency band rather than a separate qualitative
      judgement.
- category: Neurologic
  name: Gait disturbance
  description: >-
    Abnormal gait is the most common way leg-onset disease first presents, with
    foot inversion or abnormal flexion of the knee or hip appearing during
    walking before dystonia is evident at rest. Gait also responds least well to
    pallidal stimulation, so it is often the residual disability after treatment.
  phenotype_term:
    preferred_term: Dystonic gait disturbance
    term:
      id: HP:0001288
      label: Gait disturbance
  evidence:
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "presenting as a change in gait (e.g., foot inversion or abnormal flexion of the knee or hip)"
    explanation: Describes the specific gait abnormality of leg-onset disease.
- category: Neurocognitive
  name: Largely preserved cognition with isolated executive dysfunction
  description: >-
    Cognition in DYT1 dystonia is largely intact. This is a defining negative
    feature - it is what makes the disease an isolated dystonia rather than a
    complex neurodevelopmental syndrome, and it separates this entry from
    KMT2B-related dystonia, where developmental delay and intellectual disability
    are usual. The qualification is that isolated executive dysfunction is
    reported, and that abnormal temporal and spatial discrimination thresholds are
    present in unaffected relatives and non-manifesting carriers as well, so they
    are endophenotypes of the genotype rather than consequences of the dystonia.
    Note that high-dose anticholinergic treatment can itself impair memory, so a
    cognitive complaint in a treated patient is not necessarily disease-related.
  phenotype_term:
    preferred_term: Isolated executive dysfunction on a background of intact cognition
    term:
      id: HP:0033051
      label: Impaired executive functioning
  evidence:
  - reference: PMID:28627117
    reference_title: The cognitive features of idiopathic and DYT1 dystonia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "In idiopathic or DYT1 dystonia, cognition is largely intact with only isolated executive dysfunction."
    explanation: >-
      States both halves of the claim - that cognition is broadly preserved and
      that the exception is executive function. REVIEW_SYNTHESIS because the
      publication is a literature review rather than a primary cognitive study.
  - reference: PMID:28627117
    reference_title: The cognitive features of idiopathic and DYT1 dystonia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "considered endophenotypes of the disorder because deficits are also shown by unaffected relatives and nonmanifesting carriers of the DYT1 mutation"
    explanation: >-
      Supports treating the discrimination-threshold abnormalities as
      genotype-linked endophenotypes present without manifest dystonia, rather
      than as cognitive sequelae of the movement disorder.
  - reference: PMID:28627117
    reference_title: The cognitive features of idiopathic and DYT1 dystonia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Anticholinergic medication in high doses can be associated with memory impairment in dystonia."
    explanation: >-
      Supports the treatment-related confounder noted in the description, which
      matters because high-dose trihexyphenidyl is standard therapy here.
- category: Neurologic
  name: Status dystonicus
  description: >-
    The one manifestation of this disease that is an emergency. Status dystonicus
    is a crescendo of generalized dystonic contractions severe enough to require
    emergent hospitalization, and it carries a risk of rhabdomyolysis, respiratory
    compromise and metabolic decompensation. In DYT-TOR1A it occurs but is not
    common, and recording it is a deliberate counterweight to the rest of this
    entry: a disease with normal cognition, normal life span and no degeneration
    still has a state in which a patient can die.
  phenotype_term:
    preferred_term: Status dystonicus
  review_notes: >-
    No ontology term is bound, and this is a recorded negative rather than an
    omission. HPO was searched through the working ols:hp adapter for
    `l~dystonicus`, `l~status dystonicus`, `l~dystonic storm`, `l~dystonic
    crisis` and `l~dystonic attack`; all five returned nothing, while the control
    search `l~dystonia` on the same adapter returned 17 terms (HP:0001332,
    HP:0002530, HP:0007325, HP:0012179, HP:0031008, HP:0002268, HP:0031007,
    HP:0012048, HP:0002451, HP:0004373, HP:0012049, HP:0031959, HP:0031960 and
    four seizure-with-dystonia terms), so the negative result is a fact about
    HPO and not about the adapter. HP:0001332 Dystonia was considered and
    rejected: it names the sign this entry already binds at several levels of
    specificity and would say nothing about the emergency state, which is the
    whole content of this phenotype.

    frequency is also deliberately absent. The source says only "can occur but
    is not common", and every band in FrequencyEnum carries a numeric range
    (OCCASIONAL 5-29%, VERY_RARE <5%), so selecting one would manufacture a
    figure the source does not give. Contrast the Persistent focal dystonia
    phenotype in this entry, whose OCCASIONAL band rests on an explicit
    "approximately 20%".

    No causal edge points at this node. "The most severe manifestation of
    dystonia" is dystonia at its extreme rather than a downstream consequence of
    it, so a sequela edge from Generalized dystonia would assert an escalation
    relation the source does not state.
  evidence:
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Status dystonicus, the most severe manifestation of dystonia that requires emergent hospitalization, can occur but is not common in DYT-TOR1A."
    explanation: >-
      States the phenotype, its severity, the level of care it demands, and that
      it is uncommon in this specific genotype rather than in dystonia at large.
      REVIEW_SYNTHESIS because GeneReviews is summarising the reported cohorts.
- category: Musculoskeletal
  name: Joint contracture
  description: >-
    Fixed shortening of muscle and joint capsule following prolonged dystonic
    posturing. This is a secondary complication of the movement disorder rather
    than a primary feature of the genotype, which is exactly why it belongs in the
    entry: it is the part of the disability that is preventable, and preventing it
    is the stated reason for treating and referring early rather than waiting.
  phenotype_term:
    preferred_term: Joint contracture
    term:
      id: HP:0034392
      label: Joint contracture
  evidence:
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Timely medical intervention and appropriate referral for consideration of globus pallidus internus deep brain stimulation is recommended to optimally treat manifestations, minimize disability, and prevent long-term orthopedic complications such as joint contractures or spine deformities."
    explanation: >-
      Names joint contracture as a long-term orthopedic complication of untreated
      disease. INDIRECT because the sentence is framed as a treatment goal, and
      the occurrence of the complication follows from its being something
      treatment is meant to prevent; OTHER because a GeneReviews management
      recommendation is expert guidance rather than a reported study.
- category: Musculoskeletal
  name: Kyphoscoliosis
  description: >-
    Spinal deformity arising from sustained asymmetric dystonic load on the axial
    skeleton during growth. Like contracture it is a secondary consequence, and it
    is the one that most sharply limits what late intervention can achieve: once
    the curve is structural, relieving the dystonia that produced it does not undo
    it.
  phenotype_term:
    preferred_term: Kyphoscoliosis
    term:
      id: HP:0002751
      label: Kyphoscoliosis
  evidence:
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Physiatry and physical therapy to tailor exercise programs to maintain function and prevent secondary orthopedic complications (e.g., joint contractures, hip dislocation, and/or kyphoscoliosis), provide adaptative aids, and support and maintain ambulation"
    explanation: >-
      Names kyphoscoliosis specifically among the secondary orthopedic
      complications that physiatry and physical therapy are directed at, which is
      more precise than the same chapter's "spine deformities" phrasing.
      INDIRECT and OTHER for the same reasons as the contracture item.
- category: Musculoskeletal
  name: Hip dislocation
  description: >-
    Displacement of the hip joint under sustained dystonic posturing during
    skeletal growth. The third of the secondary orthopedic complications named as
    a target of physiatry and physical therapy, and the one most directly tied to
    loss of ambulation.
  phenotype_term:
    preferred_term: Hip dislocation
    term:
      id: HP:0002827
      label: Hip dislocation
  evidence:
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Physiatry and physical therapy to tailor exercise programs to maintain function and prevent secondary orthopedic complications (e.g., joint contractures, hip dislocation, and/or kyphoscoliosis), provide adaptative aids, and support and maintain ambulation"
    explanation: >-
      Names hip dislocation among the secondary orthopedic complications that
      rehabilitation is directed at preventing, and ties the prevention goal to
      maintaining ambulation. INDIRECT and OTHER as above.
genetic:
- name: TOR1A
  gene_term:
    preferred_term: TOR1A
    term:
      id: hgnc:3098
      label: TOR1A
  relationship_type: CAUSATIVE
  notes: >-
    TOR1A on chromosome 9q34 encodes torsinA, an AAA+ ATPase of the endoplasmic
    reticulum lumen and perinuclear space. The disease is caused almost entirely
    by one recurrent allele - the in-frame c.907_909delGAG deletion in exon 5,
    removing a single glutamate from a conserved C-terminal region - which is
    found in more than 98% of affected individuals and has arisen independently in
    several ethnic populations. In Ashkenazi Jews a single founder copy of that
    allele, roughly 350 years old, accounts for more than 90% of early-onset
    cases. Carriers are heterozygous; penetrance is about 30%.
  review_notes: >-
    TOR1A is hgnc:3098, verified against the local HGNC build and independently
    against MONDO's own RO:0004003 causal-gene relation for MONDO:0007492. It is
    not TOR1AIP1 (hgnc:29456) or TOR1AIP2 (hgnc:24055), which encode the LAP1
    cofactor family and are separate disease genes.
  evidence:
  - reference: PMID:9288096
    reference_title: "The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study identifies the DYT1 gene on human chromosome 9q34 as being responsible for this dominant disease."
    explanation: >-
      The gene-identification paper establishing the causal locus and the dominant
      mode of transmission.
  - reference: PMID:9288096
    reference_title: "The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Almost all cases of early-onset dystonia have a unique 3-bp deletion that appears to have arisen idependently in different ethnic populations."
    explanation: >-
      Establishes that one recurrent allele accounts for nearly all disease and
      that it is recurrent rather than descended from a single global founder.
      Quoted verbatim including the source's typographical error in
      "idependently", as an evidence snippet must never be corrected.
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of DYT-TOR1A is established in a proband with suggestive findings and a heterozygous pathogenic variant in TOR1A identified by molecular genetic testing."
    explanation: >-
      States the diagnostic criterion and the heterozygous state of the causal
      variant.
  - reference: PMID:7719342
    reference_title: "Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our data show that the vast majority (> 90%) of early-onset ITD cases in the Ashkenazi population are due to a single founder mutation, which we estimate first appeared approximately 350 years ago."
    explanation: >-
      Establishes the Ashkenazi founder effect, which coexists with the recurrent
      origin of the same deletion elsewhere.
- name: TOR1A p.D216H
  gene_term:
    preferred_term: TOR1A
    term:
      id: hgnc:3098
      label: TOR1A
  relationship_type: MODIFIER
  variant_origin: GERMLINE
  association: >-
    Intragenic modifier of penetrance of the c.907_909delGAG allele. The 216H
    allele carried in trans is highly protective; the D216 allele in cis appears
    to be required for the deletion to be penetrant.
  notes: >-
    D216H (rs1801968) is a common coding polymorphism in TOR1A itself - the same
    gene as the causative allele, which is why the effect is described as
    intragenic rather than as a second locus. The histidine allele is present on
    roughly 12% of control chromosomes, so this is ordinary population variation
    rather than a rare modifier allele.

    The direction is protective, and the effect is phase-dependent, which is the
    unusual part. In a case-control comparison of manifesting against
    non-manifesting GAG-deletion carriers, the 216H allele was enriched in
    carriers without dystonia and depleted in carriers with it; haplotype
    analysis localized the protective effect to the H allele in trans with the
    deletion, with suggestive evidence that D216 in cis is needed for penetrance
    at all. The authors' derived figures are a penetrance of about 35% for a
    carrier with D216 in trans against about 3% for one with 216H.

    relationship_type is MODIFIER rather than PROTECTIVE because the claim is
    about penetrance of another allele rather than about risk of disease in the
    general population, and because "gene modifier" is the cited study's own
    framing. Both values would be defensible; MODIFIER is the one that matches
    what the evidence measures.

    This does not close the penetrance question, and the entry does not let it
    look as though it does. The same paper states that 216H explains only a small
    proportion of the reduced penetrance and that nearly all manifesting carriers
    were D216 homozygotes, so what modulates severity among those who do manifest
    is still unaccounted for. That is recorded on the
    dyt1_reduced_penetrance_determinants discussion.
  review_notes: >-
    hgnc:3098 is the same identifier as the causative record above, deliberately:
    D216H lies in TOR1A. The CURIE and label were read from cache/hgnc/terms.csv
    in the same step as writing them, not recalled.

    The primary paper was located by independent PubMed search and fetched with
    `just fetch-reference PMID:17503336`; the cache carries green open-access
    full text from PMC, and its title, journal, year and content were read before
    quoting.
  evidence:
  - reference: PMID:17503336
    reference_title: "Intragenic Cis and Trans modification of genetic susceptibility in DYT1 torsion dystonia."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Analysis of haplotypes demonstrated a highly protective effect of the H allele in trans with the GAG deletion; there was also suggestive evidence that the D216 allele in cis is required for the disease to be penetrant."
    explanation: >-
      The result that establishes the modifier and, unusually, its phase
      dependence - protective in trans, permissive in cis. This is the sentence
      the MODIFIER classification rests on.
  - reference: PMID:17503336
    reference_title: "Intragenic Cis and Trans modification of genetic susceptibility in DYT1 torsion dystonia."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "found the frequency of the 216H allele to be increased in GAG-deletion carriers without dystonia and to be decreased in carriers with dystonia, compared with the control individuals"
    explanation: >-
      The underlying observation: the protective allele is enriched in
      non-manifesting carriers and depleted in manifesting ones, measured against
      controls. Cited separately from the haplotype analysis because it is the
      raw association rather than the phase-resolved inference drawn from it.
  - reference: PMID:17503336
    reference_title: "Intragenic Cis and Trans modification of genetic susceptibility in DYT1 torsion dystonia."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Our findings establish, for the first time, a clinically relevant gene modifier of DYT1."
    explanation: >-
      The authors' own characterization of what they found, which is where the
      MODIFIER relationship_type and the word "modifier" in this record come
      from rather than from a curator's paraphrase.
environmental:
- name: Immobilization of a dystonic body part by bracing or casting
  description: >-
    The one iatrogenic circumstance GeneReviews tells clinicians to avoid in this
    disease. Splinting, bracing or casting a limb affected by dystonia - the
    intuitive orthopaedic response to a fixed abnormal posture, and a plausible
    one given that contracture and spinal deformity are real complications here -
    can make the dystonia worse. It is modelled as an environmental influence
    rather than buried in a treatment note because it is an exposure the patient
    undergoes, it has a direction of effect, and it acts on a named node of this
    entry's pathograph.

    The exception the source preserves is "unless medically necessary": this is
    not a prohibition, for instance after a fracture, but a caution against
    immobilization chosen as a way of managing the dystonia itself. The practical
    corollary sits with the rehabilitation entries in `treatments:` - the
    GeneReviews management pathway is active exercise programmes and adaptive
    aids, not restraint.
  influences_mechanisms:
  - target: Limb-onset dystonia
    environmental_effect: EXACERBATES
    causal_link_type: DIRECT
    description: >-
      Immobilizing the affected part worsens the dystonia in that part. The link
      is drawn to the limb-onset node because the limb is what gets braced or
      cast, but the source states it for any body region affected by dystonia.
    evidence:
    - reference: PMID:20301665
      reference_title: DYT-TOR1A.
      supports: SUPPORT
      directness: DIRECT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: "Unless medically necessary, avoid immobilization with bracing or casting of the parts of the body affected by dystonia, which can worsen dystonia."
      explanation: >-
        States the exacerbating effect of the exposure on the dystonia directly,
        which is what the EXACERBATES predicate on this link asserts, and
        preserves the medical-necessity exception.
  review_notes: >-
    No exposure_term is bound, and this is a recorded negative rather than an
    un-researched gap. ECTO was searched through the ols:ecto adapter for
    `l~immobil`, `l~immobilization`, `l~immobilisation`, `l~brace`, `l~cast`,
    `l~splint`, `l~orthosis`, `l~orthotic`, `l~restraint` and `l~bandage`; every
    one returned nothing. The control search `l~arsenic` on the same adapter
    returned seven terms (ECTO:7000087, ECTO:0080000, ECTO:0900004, ECTO:0900207,
    ECTO:9000032, ECTO:9002355, ECTO:9002674), so the empty results are a fact
    about ECTO rather than a broken adapter or an unpopulated local cache.

    `l~plaster` does return ECTO:7000038 exposure to plaster, with children
    ECTO:7000039 exposure to cement plaster and ECTO:7000040 exposure to lime
    plaster. It is rejected on positive grounds: that branch is occupational
    contact with plaster as a building material, not a limb held in a plaster
    cast, so binding it would assert the wrong exposure. No term beats a wrong
    one, and exposure_term is omitted entirely rather than left as a free-text
    preferred_term, which would read as grounded without being grounded.
  evidence:
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Unless medically necessary, avoid immobilization with bracing or casting of the parts of the body affected by dystonia, which can worsen dystonia."
    explanation: >-
      The GeneReviews "Agents/circumstances to avoid" recommendation, which is the
      entire basis for this record. Graded OTHER because it is expert management
      guidance rather than a reported study, and REVIEW_SYNTHESIS because the
      chapter is synthesising practice it did not itself measure.
treatments:
- name: Bilateral pallidal deep brain stimulation
  description: >-
    Chronic high-frequency electrical stimulation delivered through electrodes
    implanted bilaterally in the internal globus pallidus. This is the defining
    intervention for the disease and the reason DYT1 dystonia, despite having no
    disease-modifying therapy, is one of the more treatable severe movement
    disorders. Efficacy in generalized and segmental dystonia is established by a
    randomized sham-controlled trial, and DYT1-specific series report large
    sustained improvements in Burke-Fahn-Marsden movement scores. Shorter disease
    duration predicts better outcome, which is the practical argument for early
    referral rather than a last resort after years of failed medication. It is
    symptomatic: it modulates network output and does nothing about torsinA.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: bilateral globus pallidus internus deep brain stimulation
    term:
      id: NCIT:C21024
      label: Deep Brain Stimulation
  target_mechanisms:
  - target: Basal Ganglia and Cerebellothalamocortical Network Dysfunction
    description: >-
      Stimulation is delivered into the pallidal output node of the network this
      entry identifies as the convergence point, altering its signalling. That
      the intervention works at this node is also the main indirect argument for
      placing the node on the causal path to the movement disorder.
  - target: Generalized dystonia
    description: >-
      The clinical target: large reductions in Burke-Fahn-Marsden movement and
      disability scores across the generalized distribution.
  notes: >-
    NCIT:C21024 is an action term reachable from NCIT:C25218 (via NCIT:C49236
    Therapeutic Procedure, checked with runoak), so it sits in the TreatmentTerm
    slot legitimately and no device-term workaround is needed here - unlike the
    cochlear-implant case, where the obvious NCIT term names equipment. No
    separate device qualifier is attached because the action term already names
    the intervention at the right granularity; the implanted pulse generator is
    not a distinct therapeutic claim.

    The KB binds NCIT:C21024 with therapeutic_modality DEVICE in all 19 other
    entries that use it, including Cervical_Dystonia and Torsion_Dystonia_6, and
    this entry follows that convention.
  evidence:
  - reference: PMID:17093249
    reference_title: "Pallidal deep-brain stimulation in primary generalized or segmental dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bilateral pallidal neurostimulation for 3 months was more effective than sham stimulation in patients with primary generalized or segmental dystonia."
    explanation: >-
      The randomized sham-controlled result, which is the highest-quality
      evidence available for this intervention and the reason it is stated
      without hedging.
  - reference: PMID:17093249
    reference_title: "Pallidal deep-brain stimulation in primary generalized or segmental dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Three months after randomization, the change from baseline in the mean (+/-SD) movement score was significantly greater in the neurostimulation group (-15.8+/-14.1 points) than in the sham-stimulation group (-1.4+/-3.8 points, P<0.001)."
    explanation: >-
      Quantifies the effect against sham on the Burke-Fahn-Marsden movement
      subscore, the standard outcome measure in this field.
  - reference: PMID:22811083
    reference_title: "Shorter disease duration correlates with improved long-term deep brain stimulation outcomes in young-onset DYT1 dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pallidal DBS was well tolerated and highly effective, with mean Burke-Fahn-Marsden Dystonia Rating Scale movement scores improving from baseline by 61.5% (P < .001) at 1 year, 64.4% (P < .001) at 2 years, and 70.3% (P < .001) at the final follow-up visit"
    explanation: >-
      DYT1-genotyped long-term outcome data, establishing that the benefit is
      large and sustained rather than transient - the sham-controlled trial above
      was only three months and was not genotype-restricted.
  - reference: PMID:22811083
    reference_title: "Shorter disease duration correlates with improved long-term deep brain stimulation outcomes in young-onset DYT1 dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our findings highlight the sustained benefit from DBS and the importance of early referral for DBS in children with medically refractory DYT1 primary torsion dystonia, which can lead to improved long-term benefits."
    explanation: >-
      Supports the early-referral recommendation, which is the clinically
      actionable consequence of duration predicting outcome.
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Timely medical intervention and appropriate referral for consideration of globus pallidus internus deep brain stimulation is recommended to optimally treat manifestations, minimize disability, and prevent long-term orthopedic complications such as joint contractures or spine deformities."
    explanation: >-
      The authoritative source for the early-referral point, which until now
      rested in this entry on a single-centre outcome series (PMID:22811083). It
      also adds a reason for referring early that the outcome series does not
      give: not only that the stimulation works better with shorter disease
      duration, but that waiting allows fixed orthopedic complications to
      accumulate, which relieving the dystonia afterwards does not undo. Those
      complications are curated as sequelae of Generalized dystonia. Graded OTHER
      and REVIEW_SYNTHESIS because a GeneReviews management recommendation is
      expert guidance rather than a study reporting data.
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "A movement disorder specialist should be involved at an early stage to discuss pharmacologic and/or surgical treatment options to relieve manifestations of dystonia."
    explanation: >-
      Records that the referral pathway begins with specialist involvement rather
      than with the operation, which is what makes "early referral" actionable for
      the general paediatrician or neurologist who sees the child first. INDIRECT
      because the sentence is about who should decide rather than about this
      intervention's effect.
  - reference: PMID:33488508
    reference_title: "Pallidal Deep Brain Stimulation for Monogenic Dystonia: The Effect of Gene on Outcome."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "They found DYT1 patients improved by 67.5% in BFMDS compared with 55.8% for non-DYT, and in multivariate analysis DYT1 was in independent predictor of superior outcome, along with shorter disease duration and lower baseline severity score"
    explanation: >-
      Records the meta-regression finding that the DYT1 genotype itself predicts
      better response. INDIRECT and REVIEW_SYNTHESIS because the quote is this
      review's account of another group's meta-regression rather than its own
      measurement. Quoted verbatim including the source's "was in independent
      predictor" typographical error.
  - reference: PMID:33488508
    reference_title: "Pallidal Deep Brain Stimulation for Monogenic Dystonia: The Effect of Gene on Outcome."
    supports: REFUTE
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "there are important exceptions where secondary worsening of dystonia may occur"
    explanation: >-
      Recorded as REFUTE against an unqualified reading of durable benefit. A
      recognised subgroup deteriorates years after an initially good response, so
      the sustained-benefit claim above is not universal. Kept as its own item
      rather than folded into an explanation, because it cuts the other way.
- name: Trihexyphenidyl
  description: >-
    High-dose oral trihexyphenidyl, a non-selective muscarinic acetylcholine
    receptor antagonist, is the preferred small-molecule treatment. Its rationale
    is mechanistic rather than incidental: striatal cholinergic interneurons are
    the cell type implicated by the mouse work in this entry, and antimuscarinic
    treatment reduces dystonic movements in those mice. In Dyt1 knock-in mice
    trihexyphenidyl also restores the reduced striatal dopamine release, through
    a nicotinic-receptor-dependent route, which links the drug to two of the
    nodes above. Its limitation is tolerability: the doses needed are high and
    antimuscarinic side effects are dose-limiting, including memory impairment.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: trihexyphenidyl
      term:
        id: CHEBI:9720
        label: Trihexyphenidyl
  target_mechanisms:
  - target: Striatal Cholinergic Interneuron Dysfunction
    description: >-
      Muscarinic blockade acts directly on the striatal cholinergic node, which
      is the node the drug's mechanism of action is defined against.
  - target: Reduced Striatal Dopamine Release
    description: >-
      Trihexyphenidyl restores dopamine release in Dyt1 knock-in mice via
      nicotinic receptors, so it also acts on the dopaminergic node downstream.
  evidence:
  - reference: PMID:30707939
    reference_title: "Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: BACKGROUND
    snippet: "Trihexyphenidyl, a nonselective muscarinic receptor antagonist, is the small molecule drug of choice for the treatment of DYT1 dystonia, but it is poorly tolerated due to significant side effects."
    explanation: >-
      States both the drug's first-line status in this specific disease and its
      tolerability limitation. Marked BACKGROUND because the sentence is the
      paper's framing of clinical practice, not a result of its rodent
      experiments; evidence_source stays MODEL_ORGANISM because the publication
      is a mouse study.
  - reference: PMID:30707939
    reference_title: "Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "THP restored DA release in Dyt1 mice through a nAChR-dependent mechanism, suggesting a mechanism of action for THP in the treatment of dystonia and identifying nAChRs as a therapeutic target."
    explanation: >-
      Supplies the mechanism of action behind the second target_mechanisms link.
      INDIRECT because the demonstration is in mouse striatal slices and in vivo
      microdialysis, so its application to the human drug effect is an inference.
  - reference: PMID:26052670
    reference_title: "Forebrain deletion of the dystonia protein torsinA causes dystonic-like movements and loss of striatal cholinergic neurons."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "murine dystonic-like movements are reduced significantly with an antimuscarinic agent used clinically"
    explanation: >-
      Behavioural evidence that antimuscarinic treatment works on the movements
      themselves, not only on a neurochemical readout. INDIRECT because the
      result is in a conditional-knockout mouse rather than in patients.
- name: Botulinum toxin chemodenervation
  description: >-
    Intramuscular botulinum neurotoxin injection into individually disabling
    dystonic muscles. In a generalized dystonia it cannot address the whole
    distribution, so its role here is adjunctive - targeting a residual focal
    problem, including one persisting after pallidal stimulation - rather than
    primary. It acts at the neuromuscular junction, the furthest possible point
    downstream of the torsinA lesion.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: botulinum toxin chemodenervation
    term:
      id: NCIT:C157775
      label: Botulinum Toxin Therapy
  target_mechanisms:
  - target: Limb-onset dystonia
    description: >-
      Blocks acetylcholine release at the neuromuscular junction of the injected
      muscle, reducing contraction in that muscle only. Purely symptomatic and
      distal to every mechanistic node in this entry.
  notes: >-
    therapeutic_modality is OTHER rather than SMALL_MOLECULE: botulinum
    neurotoxin is a ~150 kDa bacterial protein, so SMALL_MOLECULE would be
    factually wrong and PEPTIDE nearly as wrong at that size. This follows the
    reasoning recorded on the same treatment in Torsion_Dystonia_6, which also
    notes that the KB is inconsistent on this point.

    therapeutic_agent is left absent. NCIT:C163032 Botulinum Toxin exists, but
    the cited source is a cognitive-outcomes review that names the modality
    without specifying a serotype or product, so binding a specific agent would
    assert more than the evidence carries.
  evidence:
  - reference: PMID:28627117
    reference_title: The cognitive features of idiopathic and DYT1 dystonia.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "The successful treatment of dystonia with botulinum toxin injections or deep brain stimulation does not produce any major adverse effects on cognition."
    explanation: >-
      The only quotable statement in the fetched reference set that bears on
      botulinum toxin in this disease. It establishes that the treatment is used
      and can be successful, and that it does not carry a cognitive penalty -
      relevant given that the oral alternative does. INDIRECT because the
      sentence is about cognitive safety rather than motor efficacy, and no
      motor-efficacy quote for botulinum toxin in DYT1 specifically was found in
      the references fetched for this entry.
- name: Physiatry and physical therapy
  description: >-
    Tailored exercise programmes, adaptive aids and gait support, directed by
    physical medicine and rehabilitation. Its purpose here is specific and worth
    stating precisely: it does not treat the dystonia, it treats what sustained
    dystonic posturing does to the musculoskeletal system. That makes it the one
    intervention in this entry aimed at the secondary complications - contracture,
    hip displacement, spinal deformity - rather than at the movement disorder,
    which is also why it runs alongside pallidal stimulation rather than competing
    with it.

    Note the direction of the contrast with the environmental record in this
    entry: the rehabilitation pathway is active exercise and adaptation, whereas
    immobilizing a dystonic part can worsen the dystonia.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: physiatry and physical therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  target_mechanisms:
  - target: Joint contracture
    description: >-
      Range-of-motion and stretching programmes are directed at preventing fixed
      contracture in joints held in sustained dystonic posture.
  - target: Kyphoscoliosis
    description: >-
      Postural and trunk-directed exercise is aimed at limiting the spinal
      deformity that asymmetric axial dystonic load produces during growth.
  - target: Hip dislocation
    description: >-
      Positioning and strengthening are directed at keeping the hip loaded
      normally enough to prevent displacement.
  - target: Gait disturbance
    description: >-
      Gait training and adaptive aids support and maintain ambulation, which the
      source names as an explicit goal of physical therapy. Relevant because gait
      is also the feature that responds least well to pallidal stimulation and so
      is often the residual disability.
  notes: >-
    therapeutic_modality is BEHAVIORAL on the mechanical rule in CLAUDE.md, which
    maps NCIT:C15302 physical therapy to that value. It reads oddly for an
    exercise programme, but the enum's own definition of BEHAVIORAL explicitly
    covers a "behavioral, physical, dietary, or lifestyle intervention", so
    physical therapy is inside it by definition rather than by stretch.

    preferred_term is deliberately more specific than the bound label: the
    intervention as GeneReviews describes it is physiatry directing physical
    therapy, and NCIT:C15302 names only the therapy. The specificity is carried in
    preferred_term rather than by reaching for a term that does not mean this.
  evidence:
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Physiatry and physical therapy to tailor exercise programs to maintain function and prevent secondary orthopedic complications (e.g., joint contractures, hip dislocation, and/or kyphoscoliosis), provide adaptative aids, and support and maintain ambulation"
    explanation: >-
      Establishes the intervention, its four stated goals, and the three specific
      complications it is directed against - which is where this treatment's
      target_mechanisms links come from rather than from a curator's inference
      about what rehabilitation is for. Graded OTHER and REVIEW_SYNTHESIS as
      expert management guidance. Quoted verbatim including the chapter's
      "adaptative" for adaptive.
- name: Occupational therapy
  description: >-
    Therapy directed at the fine motor tasks of daily life - feeding, grooming,
    dressing and writing. It matters disproportionately in this disease because
    writing is both a common presenting complaint and, in the roughly one in five
    patients whose dystonia stays focal, often the whole of the disability.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: occupational therapy
    term:
      id: NCIT:C121351
      label: Occupational Therapy
  target_mechanisms:
  - target: Writer's cramp
    description: >-
      Writing is one of the fine motor skills the source names as an explicit
      target of occupational therapy, and writer's cramp is the form this
      entry's task-specific upper-limb dystonia takes.
  notes: >-
    therapeutic_modality is BEHAVIORAL on the same mechanical rule that covers
    physical therapy, which maps NCIT:C121351 occupational therapy to that value.
    therapeutic_agent is absent because the intervention is non-pharmacological.
  evidence:
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "occupational therapy to address fine motor skills (e.g., feeding, grooming, dressing, and writing)"
    explanation: >-
      Names the intervention and the fine motor domains it addresses, including
      writing, which is the basis for the link to writer's cramp. Graded OTHER and
      REVIEW_SYNTHESIS as expert management guidance.
diagnosis:
- name: Targeted TOR1A molecular genetic testing
  description: >-
    The diagnosis is established by finding a heterozygous pathogenic TOR1A
    variant in a proband with a suggestive clinical picture. This disease is
    unusually favourable for targeted testing rather than panel or exome
    sequencing, because more than 98% of affected individuals carry the same
    c.907_909delGAG allele - so a single-variant assay answers the question in
    nearly every case, and a negative targeted result is informative rather than
    merely uninformative.

    Two consequences of the genetics govern how the result is read, and both are
    curated elsewhere in this entry. Penetrance is about 30%, so identifying the
    variant in a relative predicts dystonia in a minority of carriers and an
    unaffected parent cannot be assumed to be a non-carrier. And about 5% of
    affected individuals present after age 30, so a later presentation does not
    exclude the diagnosis.
  diagnosis_term:
    preferred_term: targeted TOR1A single-variant molecular genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  notes: >-
    NCIT:C15709 Genetic Testing was checked against cache/ncit/terms.csv for its
    label and against the treatmentactionterm enum cache for membership in the
    dynamic enum that diagnosis_term binds to, which is reachable from NCIT:C25218
    Clinical Intervention or Procedure. preferred_term carries the specificity the
    action term does not - that the assay is targeted at one variant in one gene
    rather than a broad genomic test.

    A levodopa trial to exclude dopa-responsive dystonia was considered as a second
    diagnostic item and is deliberately not curated, because no fetched source
    states it as a diagnostic step. The GeneReviews chapter does not mention
    levodopa at all, and the only fetched reference that does (PMID:30707939) is a
    mouse study whose levodopa content is a methods paragraph plus the result that
    levodopa does not increase striatal dopamine release. That result is curated
    where it belongs, on the Reduced Striatal Dopamine Release node, and it
    supports the pharmacological contrast with dopa-responsive dystonia without
    supporting a recommendation to perform a trial. Adding the item would have
    meant asserting a diagnostic pathway from a mouse experiment.
  evidence:
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of DYT-TOR1A is established in a proband with suggestive findings and a heterozygous pathogenic variant in TOR1A identified by molecular genetic testing."
    explanation: >-
      States the diagnostic criterion - clinical suspicion plus a heterozygous
      pathogenic TOR1A variant on molecular testing - which is what this
      diagnostic item is. The same sentence is cited on the TOR1A genetic record,
      where it supports the gene-disease claim; here it supports the testing
      pathway, and evidence_source is HUMAN_CLINICAL in both places because the
      publication's grading cannot change with the use made of the quote.
  - reference: PMID:20301665
    reference_title: DYT-TOR1A.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "More than 98% of affected individuals have the 3-bp deletion c.907_909delGAG involving the highly conserved GAGGAG sequence in exon 5."
    explanation: >-
      The allelic homogeneity that makes targeted single-variant testing an
      adequate first-line strategy here, where in most Mendelian diseases it
      would not be. INDIRECT because the sentence reports the allele distribution
      and the testing strategy follows from it rather than being stated.
clinical_trials:
- name: NCT00142259
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: >-
    The randomized, sham-controlled trial of bilateral internal globus pallidus
    stimulation in primary generalized or segmental dystonia reported by Kupsch
    and colleagues (PMID:17093249). Forty patients received an implanted device
    and were randomized to active or sham stimulation for three months, with
    blinded video assessment, followed by open-label active stimulation for all.
  target_phenotypes:
  - preferred_term: Generalized dystonia
    term:
      id: HP:0007325
      label: Generalized dystonia
  notes: >-
    phase is NOT_APPLICABLE because this is a device study that does not follow
    the FDA drug-phase classification, which is the case that enum value exists
    for. The trial was not restricted to TOR1A carriers, so it establishes
    efficacy for primary generalized and segmental dystonia as a class rather
    than for this genotype specifically; the genotype-specific evidence is the
    DYT1 cohort cited on the treatment.
  evidence:
  - reference: clinicaltrials:NCT00142259
    reference_title: "Randomisierte, Doppelblinde Langzeitstudie Zur Klinischen Wirksamkeit Der Bilateralen Globus Pallidus Internus-Stimulation Bei Idiopathischer Generalisierter Oder Segmentaler Dystonie"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The purpose of this study is to evaluate the efficacy and safety of bilateral deep brain stimulation of the internal globus pallidus for treating idiopathic generalized or severe segmental dystonia."
    explanation: >-
      The registry record establishing the trial's identity, target population
      and intervention. The title is the registry's own German-language official
      title, copied verbatim from the cached record rather than translated or
      replaced with the English publication title - this is the same trial
      published in English as PMID:17093249, which is cited on the deep brain
      stimulation treatment under its own title.
animal_models:
- name: Tor1a heterozygous GAG-deletion knock-in mouse
  species: Mouse
  genotype: Tor1a+/dGAG (heterozygous in-frame GAG deletion)
  publication: PMID:30707939
  description: >-
    The genotype-matched model: a mouse carrying one copy of the same in-frame
    GAG deletion patients carry. It is the model that ought to reproduce the
    disease and largely does not, which is the central translational problem in
    this field. It does reproduce a specific neurochemical defect - reduced
    evoked striatal dopamine release, correctable with trihexyphenidyl - so it is
    informative for that node while failing at the level of overt pathology and
    dystonia.
  modeled_mechanisms:
  - target: Reduced Striatal Dopamine Release
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: >-
      Directly measures reduced evoked dopamine release in the striatum of a
      mouse carrying the human allele, by ex vivo fast-scan cyclic voltammetry
      and in vivo microdialysis.
    limitations: >-
      The corresponding human data are reduced striatal D2 receptor density and
      altered dopamine metabolites, not a direct measurement of evoked release,
      so the human and mouse readouts are related but not the same quantity.
    readouts:
    - name: Evoked striatal dopamine release
      target: Reduced Striatal Dopamine Release
      direction: DECREASED
      interpretation: >-
        The defining measurement of this node in the model system.
      evidence:
      - reference: PMID:30707939
        reference_title: "Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "we found that DA release was significantly reduced in Dyt1 knockin mice"
        explanation: Reports the measured reduction in the knock-in genotype.
    - name: Dopamine release after trihexyphenidyl
      target: Reduced Striatal Dopamine Release
      direction: RESTORED
      interpretation: >-
        The rescue arm, which is what ties the clinically preferred drug to this
        node.
      evidence:
      - reference: PMID:30707939
        reference_title: "Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "THP restored DA release in Dyt1 mice through a nAChR-dependent mechanism"
        explanation: Reports restoration of the readout and the receptor dependence of the rescue.
    evidence:
    - reference: PMID:30707939
      reference_title: "Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "a significant reduction in striatal DA release is observed in several mouse models of DYT1 dystonia"
      explanation: >-
        Establishes that the dopamine-release defect replicates across independent
        DYT1 mouse models, which is what makes this model informative for the node
        rather than a single-laboratory observation.
  - target: Generalized dystonia
    relationship: FAILS_TO_RECAPITULATE
    fidelity: LOW
    model_scale: ORGANISM
    description: >-
      The genotype that matches patients does not produce the disease. Mice
      heterozygous for the identical deletion show no pathology, so the model
      cannot be used to study how the allele produces dystonia, only what it does
      to particular cellular readouts.
    limitations: >-
      This is a species difference rather than an allele or dosage artefact: the
      deletion is the human one and the zygosity is the human one. Pathology in
      mice requires homozygosity or conditional deletion, neither of which is the
      human genetic state, so every downstream mouse result in this entry is
      obtained from a genotype patients do not have.
    evidence:
    - reference: PMID:33468570
      reference_title: "Disease Modeling with Human Neurons Reveals LMNB1 Dysregulation Underlying DYT1 Dystonia."
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: BACKGROUND
      snippet: "significant species-dependent differences exist since animals with the identical heterozygous mutation fail to show pathology"
      explanation: >-
        States the negative result directly and attributes it to species
        difference, which is the substance of this FAILS_TO_RECAPITULATE link.
        Graded IN_VITRO because the publication is a human iPSC study; BACKGROUND
        because this sentence is its motivation for using human neurons rather
        than one of its own results.
- name: TorsinA-null and homozygous knock-in mouse neurons
  species: Mouse
  genotype: Tor1a-/- and Tor1a dGAG/dGAG
  publication: PMID:16364897
  description: >-
    The models in which the nuclear envelope lesion was discovered. Complete loss
    of torsinA, or homozygosity for the disease deletion, produces severely
    abnormal nuclear membranes specifically in neurons, with non-neuronal cells
    appearing normal - the observation that made nuclear envelope biology the
    dominant mechanistic account of this disease and that explains how a
    ubiquitously expressed gene causes a neurological illness.
  modeled_mechanisms:
  - target: Neuronal Nuclear Envelope Disruption
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: >-
      Demonstrates the nuclear envelope lesion and its neuron-selectivity, and
      establishes its developmental timing.
    limitations: >-
      The genotypes are homozygous null or homozygous deletion; patients are
      heterozygous, and heterozygous mice show no pathology. The specific
      morphology seen here - perinuclear blebs - is also not what patient-derived
      human neurons show, so the node is supported but its mouse morphology should
      not be assumed to transfer. Fidelity is MODERATE rather than HIGH for those
      two reasons together.
    readouts:
    - name: Neuronal nuclear membrane morphology
      target: Neuronal Nuclear Envelope Disruption
      direction: ALTERED
      interpretation: >-
        The structural lesion defining the node, restricted to neurons.
      evidence:
      - reference: PMID:16364897
        reference_title: "Loss of the dystonia-associated protein torsinA selectively disrupts the neuronal nuclear envelope."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "contain severely abnormal nuclear membranes, although non-neuronal cell types appear normal"
        explanation: Reports the morphological measurement and its cell-type restriction.
    evidence:
    - reference: PMID:16364897
      reference_title: "Loss of the dystonia-associated protein torsinA selectively disrupts the neuronal nuclear envelope."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "These observations demonstrate that neurons have a unique requirement for nuclear envelope localized torsinA function and suggest that loss of this activity is a key molecular event in the pathogenesis of DYT1 dystonia."
      explanation: >-
        The authors' own statement that this model is informative for the
        pathogenesis of the human disease at this node.
- name: Forebrain conditional torsinA knockout mouse
  species: Mouse
  genotype: Conditional Tor1a deletion in embryonic forebrain cholinergic and GABAergic progenitors
  publication: PMID:26052670
  description: >-
    The model that produces an overt movement phenotype. Deleting torsinA in
    embryonic progenitors of forebrain cholinergic and GABAergic neurons causes
    dystonic-like twisting movements appearing during juvenile maturation,
    coinciding with selective loss of dorsal striatal large cholinergic
    interneurons. It is the strongest available link from torsinA loss to a
    dystonic phenotype, and the model that identified the vulnerable cell type.
  modeled_mechanisms:
  - target: Striatal Cholinergic Interneuron Dysfunction
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: >-
      Identifies the selectively vulnerable cell type and characterizes the
      surviving population as morphologically, electrophysiologically and
      connectionally abnormal.
    limitations: >-
      Conditional homozygous deletion in a defined progenitor population is not
      the human genetic state, and the cell loss seen here is more severe than
      anything reported in patients, whose striatum shows cholinergic
      abnormalities without overt degeneration.
    readouts:
    - name: Dorsal striatal large cholinergic interneuron number
      target: Striatal Cholinergic Interneuron Dysfunction
      direction: DECREASED
      interpretation: >-
        The cellular lesion whose timing coincides with symptom onset in this
        model.
      evidence:
      - reference: PMID:26052670
        reference_title: "Forebrain deletion of the dystonia protein torsinA causes dystonic-like movements and loss of striatal cholinergic neurons."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "The onset of these movements coincides with selective degeneration of dorsal striatal large cholinergic interneurons (LCI), and surviving LCI exhibit morphological, electrophysiological, and connectivity abnormalities."
        explanation: Reports the cell loss and the abnormality of survivors.
    evidence:
    - reference: PMID:26052670
      reference_title: "Forebrain deletion of the dystonia protein torsinA causes dystonic-like movements and loss of striatal cholinergic neurons."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "These findings demonstrate that dorsal LCI have a unique requirement for torsinA function during striatal maturation, and link abnormalities of these cells to dystonic-like movements in an overtly symptomatic animal model."
      explanation: >-
        The authors' statement linking this cell type to the movement phenotype,
        which is what makes the model informative for this node.
  - target: Maturation-Dependent Disruption of Neuronal Development
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: ORGANISM
    description: >-
      Shows that the phenotype is timed to juvenile CNS maturation rather than
      present from birth or acquired in adulthood, matching the childhood onset
      of the human disease.
    limitations: >-
      Mouse juvenile maturation and human childhood are matched only in ordinal
      terms; the model cannot speak to the specific age window or to why human
      onset clusters around 9 years.
    evidence:
    - reference: PMID:26052670
      reference_title: "Forebrain deletion of the dystonia protein torsinA causes dystonic-like movements and loss of striatal cholinergic neurons."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "causes dystonic-like twisting movements that emerge during juvenile CNS maturation"
      explanation: Establishes the maturation-dependent timing of the phenotype.
experimental_models:
- name: Patient-derived cholinergic motor neurons
  experimental_model_type: IPSC_DERIVED_MODEL
  publication: PMID:33468570
  description: >-
    Cholinergic motor neurons generated from DYT1 patients, either by direct
    conversion of skin fibroblasts or by differentiation of induced pluripotent
    stem cells, carrying the patient heterozygous GAG deletion in human cells.
    This is the model that works where the heterozygous mouse does not, and it is
    also the model that disagrees with the mouse about what the nuclear lesion
    looks like. Isogenic controls - genomically corrected patient lines and
    engineered deletion in healthy lines - are available and were used in the
    RANBP17 work, which is what makes the transport findings attributable to the
    allele rather than to line background.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_types:
  - preferred_term: patient-derived cholinergic motor neuron
    term:
      id: CL:0000100
      label: motor neuron
  modeled_mechanisms:
  - target: Impaired Nucleocytoplasmic Transport
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: >-
      Measures impaired transport of both protein and mRNA cargo in human cells
      carrying the patient genotype, and identifies RANBP17 loss as its
      molecular correlate with a rescue experiment.
    limitations: >-
      Cultured neurons lack the striatal circuitry the disease is about, and the
      cell type studied is a cholinergic motor neuron rather than a striatal
      cholinergic interneuron, so the transport defect is demonstrated in a
      related but not identical vulnerable population.
    readouts:
    - name: Nucleocytoplasmic transport of protein and mRNA cargo
      target: Impaired Nucleocytoplasmic Transport
      direction: DECREASED
      interpretation: >-
        The defining measurement of the node in human patient-derived cells.
      evidence:
      - reference: PMID:33468570
        reference_title: "Disease Modeling with Human Neurons Reveals LMNB1 Dysregulation Underlying DYT1 Dystonia."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "impaired nucleocytoplasmic transport (NCT) of mRNAs and proteins"
        explanation: Reports the transport measurement in patient-derived neurons.
    - name: Transport activity after RANBP17 overexpression
      target: Impaired Nucleocytoplasmic Transport
      direction: RESTORED
      interpretation: >-
        The rescue that makes the transport defect causal for the developmental
        phenotype rather than merely correlated with it.
      evidence:
      - reference: PMID:38438257
        reference_title: "RANBP17 Overexpression Restores Nucleocytoplasmic Transport and Ameliorates Neurodevelopment in Induced DYT1 Dystonia Motor Neurons."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "the overexpression of RANBP17 emerged as a substantial mitigating factor, effectively restoring impaired NCT activity and rescuing neurodevelopmental deficits observed in DYT1 MNs"
        explanation: Reports restoration of both the transport readout and the developmental phenotype.
    evidence:
    - reference: PMID:38438257
      reference_title: "RANBP17 Overexpression Restores Nucleocytoplasmic Transport and Ameliorates Neurodevelopment in Induced DYT1 Dystonia Motor Neurons."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "These patient-specific neurons retain the donor's heterozygous TOR1A mutation"
      explanation: >-
        Establishes that the model carries the human disease genotype at the
        human zygosity, which is what makes it informative where the mouse is not.
  - target: Neuronal Nuclear Envelope Disruption
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: >-
      Reproduces nuclear envelope pathology - markedly thickened nuclear lamina,
      disrupted nuclear morphology, LMNB1 upregulation and mislocalization - but
      not the perinuclear blebs that are the signature lesion in the mouse
      models. It supports the node while contradicting the mouse's account of what
      the node looks like in human cells.
    limitations: >-
      The absence of blebs means the human and mouse evidence for this node are
      not interchangeable, and no patient brain tissue has confirmed either
      morphology in vivo. See the HUMAN_MODEL_MISMATCH discussion.
    readouts:
    - name: Perinuclear blebs
      target: Neuronal Nuclear Envelope Disruption
      direction: UNCHANGED
      interpretation: >-
        A real negative result: the lesion that defines the mouse models is
        absent in human patient-derived neurons.
      evidence:
      - reference: PMID:33468570
        reference_title: "Disease Modeling with Human Neurons Reveals LMNB1 Dysregulation Underlying DYT1 Dystonia."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: 'whereas they lack the perinuclear "blebs" that are often observed in animal models'
        explanation: >-
          Records the negative finding in full: the human patient-derived motor
          neurons lack the lesion that defines the mouse models.
    evidence:
    - reference: PMID:33468570
      reference_title: "Disease Modeling with Human Neurons Reveals LMNB1 Dysregulation Underlying DYT1 Dystonia."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "markedly thickened nuclear lamina, disrupted nuclear morphology"
      explanation: >-
        Reports the envelope pathology that is present, which is what licenses
        PARTIALLY_RECAPITULATES rather than FAILS_TO_RECAPITULATE.
discussions:
- discussion_id: dyt1_nuclear_envelope_model_mismatch
  kind: HUMAN_MODEL_MISMATCH
  prompt: >-
    Mouse models show perinuclear nuclear-envelope blebs and human patient-derived
    neurons do not, while heterozygous mice show no pathology at all. Which
    nuclear-envelope lesion is the one that occurs in patients, and does any of
    the mouse pathology apply to the human disease?
  attaches_to:
  - pathophysiology#Neuronal Nuclear Envelope Disruption
  - experimental_models#Patient-derived cholinergic motor neurons
  - animal_models#Tor1a heterozygous GAG-deletion knock-in mouse
  rationale: >-
    This is not a generic species caveat but a specific, twofold mismatch that
    bears on the entry's central mechanistic claim.

    First, zygosity. Patients are heterozygous. Mice heterozygous for the
    identical deletion show no pathology, so every mouse result supporting the
    nuclear-envelope account comes from a homozygous null, homozygous knock-in, or
    conditional-deletion genotype that no patient has.

    Second, morphology. Where the mouse shows perinuclear blebs or herniations,
    patient-derived cholinergic motor neurons carrying the heterozygous deletion
    show a thickened lamina, disrupted nuclear shape and LMNB1 dysregulation, and
    explicitly lack the blebs. Both are nuclear envelope pathology and it would be
    easy to treat them as the same finding, but they are different lesions, and
    the mechanism inferred from one does not automatically transfer.

    The consequence for reading this entry: the Neuronal Nuclear Envelope
    Disruption node is well supported as a category and poorly resolved as a
    specific lesion. No patient brain tissue has shown either morphology in vivo,
    which is what would settle it. The human model is not simply better than the
    mouse either - cultured motor neurons lack the striatal circuitry the disease
    is about, and the striatal cholinergic interneuron evidence runs the other
    way, existing in mouse and in postmortem patient striatum but not in the iPSC
    system.
  notes: >-
    Recorded as HUMAN_MODEL_MISMATCH rather than KNOWLEDGE_GAP because the
    evidence is not absent: both lesions are well documented in their respective
    systems, and the open question is translational validity.
- discussion_id: dyt1_reduced_penetrance_determinants
  kind: KNOWLEDGE_GAP
  prompt: >-
    Why do roughly 70% of TOR1A GAG-deletion carriers never develop dystonia,
    when functional imaging shows the same network abnormality in manifesting and
    non-manifesting carriers alike?
  attaches_to:
  - pathophysiology#Basal Ganglia and Cerebellothalamocortical Network Dysfunction
  - inheritance#Autosomal dominant with reduced penetrance
  - genetic#TOR1A p.D216H
  rationale: >-
    Reduced penetrance is usually treated as a counselling fact, but here it is
    also the sharpest mechanistic question in the disease, because the obvious
    candidate explanation has been excluded. Reduced striatal GABA and dopamine
    receptor availability, increased lentiform, supplementary motor area and
    cerebellar metabolism, and an abnormal cerebellothalamocortical pathway are
    all present in carriers irrespective of whether they manifest. So the network
    abnormality this entry places immediately upstream of the movement disorder is
    not sufficient to produce it.

    The systematic review's proposal is that the distinguishing factor lies in the
    distal thalamocortical segment, disrupted in non-manifesting carriers in a way
    that may prevent abnormal impulses reaching cortex, together with larger
    putaminal volumes that appear compensatory and a correspondingly reduced
    response to plasticity-inducing protocols. That is a hypothesis generated from
    cross-sectional imaging of small cohorts rather than an established mechanism.

    One genetic modifier is established, and it is a partial answer rather than
    none. The TOR1A coding polymorphism D216H (rs1801968) modifies penetrance of
    the GAG deletion: the 216H allele carried in trans is highly protective,
    D216 in cis appears to be required for the deletion to be penetrant at all,
    and the derived penetrance estimates are about 35% for a carrier with D216 in
    trans against about 3% for one carrying 216H. It is curated as a MODIFIER
    record in `genetic:`.

    What keeps this a knowledge gap is the size and the scope of that answer,
    stated by the same study that found it. The 216H allele has a potent effect
    but explains only a small proportion of the reduced penetrance, so most of
    the 70% is still unaccounted for. And nearly all manifesting carriers were
    D216 homozygotes, which means the modifier says nothing about the second
    question sitting beside penetrance - why, among those who do manifest,
    severity ranges from writer's cramp that never spreads to generalized
    dystonia. Beyond D216H this entry records no determinant of penetrance, and
    none was found in the sources fetched for it: no environmental trigger, no
    developmental variable, and no further modifier locus.

    Until this is settled, the final edge in this entry - from network dysfunction
    to dystonia - is an association plus a therapeutic argument, and the entry
    says so at that node rather than implying a closed causal chain.
  evidence:
  - reference: PMID:17503336
    reference_title: "Intragenic Cis and Trans modification of genetic susceptibility in DYT1 torsion dystonia."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Although the 216H allele has a potent effect, it explains only a small proportion of the reduced penetrance associated with carrying the DYT1 GAG-deletion mutation."
    explanation: >-
      The authors' own bound on how much their modifier explains, which is what
      keeps reduced penetrance an open question after D216H rather than a solved
      one. Cited on the gap itself so that a reader who sees the MODIFIER record
      in `genetic:` does not conclude the gap has closed.
  - reference: PMID:17503336
    reference_title: "Intragenic Cis and Trans modification of genetic susceptibility in DYT1 torsion dystonia."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Also, almost all manifesting carriers, regardless of severity, were homozygous for the D216 allele, so factors moderating the extent of disease expression in these individuals remain unknown."
    explanation: >-
      States the second, distinct gap in the authors' own words: the modifier
      stratifies who manifests, not how severely. This is the sentence behind the
      variable-expressivity half of this discussion, which is separate from the
      penetrance half and is not addressed by D216H at all.
notes: >-
  Scope and sibling entries. This is the TOR1A/DYT1 Mendelian entity.
  Torsion_Dystonia_6 is its closest relative in the KB and the two are linked
  mechanistically as well as nosologically: THAP1, the DYT6 gene, represses the
  TOR1A core promoter, so that entry carries a "Derepression of TOR1A" node.
  Clinically they separate on onset region - limb here, cranial/cervical and
  laryngeal there - and on DBS response, which is better in DYT1.
  KMT2B-Related_Dystonia is the other major childhood-onset generalized monogenic
  dystonia but is a complex dystonia with developmental delay and intellectual
  disability, where this one is isolated with largely intact cognition.
  Cervical_Dystonia covers common adult-onset sporadic focal disease and
  deliberately binds no causal gene.

  Module conformance. No pathophysiology node declares conforms_to. kb/modules/
  was listed and searched for nuclear envelope, nucleocytoplasmic transport,
  basal ganglia, dystonia and striatal mechanisms; nothing covers nuclear
  envelope dysfunction or basal ganglia motor circuit dysfunction. If a
  nuclear-envelopathy module is created later - the LMNB1 and lamina findings
  here would sit naturally beside the laminopathies - this entry's Neuronal
  Nuclear Envelope Disruption node is the conformance target.

  Prevalence. No population prevalence estimate for the disease is recorded,
  because none was found in a citable form during this curation. What is recorded
  is the Ashkenazi frequency of the founder mutation and the founder share, which
  are different quantities from disease prevalence; the ~30% penetrance means the
  manifesting rate is well below either, and no derived figure is asserted.
  Whether the 1/6,000-1/2,000 figure is a carrier or an allele frequency is not
  resolved by its source, and the prevalence record's own notes say so rather
  than presenting CARRIER_FREQUENCY as a settled reading. The Orphanet record for
  this disease (Orphanet:256, cross-referenced from MONDO:0007492) is not present
  in references_cache and `just fetch-reference ORPHA:256` reports no source for
  it, so the usual Orphanet epidemiology row was not available.

  Deep-research provenance. research/Early-onset_Generalized_Limb-onset_Dystonia-deep-research-claude_code.md
  was used as a prose outline only. Its citations were not usable: of 16 cited
  PMIDs, a title check found 10 unrelated to dystonia (including papers on E. coli
  multidrug transporters, HIV integrase inhibitors, type 1 diabetes and vertebral
  artery stenting), and its own frontmatter records 8 mislabelled ontology terms,
  among them HP:0100260 given as "Segmental dystonia" when it is Mesoaxial
  polydactyly and NCIT:C376 given as baclofen when it is Cisplatin. Every
  reference in this entry was found by independent PubMed search, fetched with
  `just fetch-reference`, and read before quoting; every ontology identifier was
  resolved against an ontology lookup in the same step it was written. Nothing was
  carried over from the report.
references:
- reference: PMID:20301665
  title: "DYT-TOR1A."
  tags:
  - GeneReviews
  findings: []

📚

References & Deep Research

References

1

PMID:20301665

DYT-TOR1A.

No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (2)

Record notes

Scope and sibling entries. This is the TOR1A/DYT1 Mendelian entity. Torsion_Dystonia_6 is its closest relative in the KB and the two are linked mechanistically as well as nosologically: THAP1, the DYT6 gene, represses the TOR1A core promoter, so that entry carries a "Derepression of TOR1A" node. Clinically they separate on onset region - limb here, cranial/cervical and laryngeal there - and on DBS response, which is better in DYT1. KMT2B-Related_Dystonia is the other major childhood-onset generalized monogenic dystonia but is a complex dystonia with developmental delay and intellectual disability, where this one is isolated with largely intact cognition. Cervical_Dystonia covers common adult-onset sporadic focal disease and deliberately binds no causal gene. Module conformance. No pathophysiology node declares conforms_to. kb/modules/ was listed and searched for nuclear envelope, nucleocytoplasmic transport, basal ganglia, dystonia and striatal mechanisms; nothing covers nuclear envelope dysfunction or basal ganglia motor circuit dysfunction. If a nuclear-envelopathy module is created later - the LMNB1 and lamina findings here would sit naturally beside the laminopathies - this entry's Neuronal Nuclear Envelope Disruption node is the conformance target. Prevalence. No population prevalence estimate for the disease is recorded, because none was found in a citable form during this curation. What is recorded is the Ashkenazi frequency of the founder mutation and the founder share, which are different quantities from disease prevalence; the ~30% penetrance means the manifesting rate is well below either, and no derived figure is asserted. Whether the 1/6,000-1/2,000 figure is a carrier or an allele frequency is not resolved by its source, and the prevalence record's own notes say so rather than presenting CARRIER_FREQUENCY as a settled reading. The Orphanet record for this disease (Orphanet:256, cross-referenced from MONDO:0007492) is not present in references_cache and `just fetch-reference ORPHA:256` reports no source for it, so the usual Orphanet epidemiology row was not available. Deep-research provenance. research/Early-onset_Generalized_Limb-onset_Dystonia-deep-research-claude_code.md was used as a prose outline only. Its citations were not usable: of 16 cited PMIDs, a title check found 10 unrelated to dystonia (including papers on E. coli multidrug transporters, HIV integrase inhibitors, type 1 diabetes and vertebral artery stenting), and its own frontmatter records 8 mislabelled ontology terms, among them HP:0100260 given as "Segmental dystonia" when it is Mesoaxial polydactyly and NCIT:C376 given as baclofen when it is Cisplatin. Every reference in this entry was found by independent PubMed search, fetched with `just fetch-reference`, and read before quoting; every ontology identifier was resolved against an ontology lookup in the same step it was written. Nothing was carried over from the report.

Create: DYT1 early-onset generalized limb-onset dystonia · 2026-09-29T23:06:05Z · View source

Curated early-onset generalized limb-onset dystonia, DYT1 (MONDO:0007492), caused by the in-frame TOR1A GAG deletion removing a glutamate from torsinA. Fills the gap among the nine dystonia entries already in the knowledge base; DYT1 is the most common inherited early-onset generalized dystonia. Models reduced (~30%) penetrance explicitly rather than glossing it, and pallidal deep brain stimulation as the defining intervention. 71 evidence snippets, all exact substrings of fetched reference caches (71/71 verified by validate-disorders). Gene binding hgnc:3098 confirmed as TOR1A by bidirectional OAK lookup rather than taken from the issue body. Deep research used the claude_code provider after the Edison account returned HTTP 402; only 6 of that report's 16 cited PMIDs had disease-relevant titles, so citations were re-derived independently.

Claude Code ▸

1. Disease Information

claude-haiku-4-5-20251001, claude-opus-4-7[1m] 2026-09-11T16:25:44.946950

1. Disease Information

Overview. Early-onset generalized limb-onset dystonia — historically Oppenheim dystonia, dystonia musculorum deformans, or DYT1 dystonia, and now designated DYT-TOR1A under the MDS 2013 nomenclature — is the most common inherited early-onset isolated (primary) generalized dystonia. It is caused, in the great majority of cases, by a heterozygous in-frame 3-bp deletion (c.907_909delGAG; p.Glu303del, also written ΔE302/303 or ΔGAG) in exon 5 of TOR1A on chromosome 9q34, which encodes the AAA+ ATPase torsinA. The disease characteristically begins in a limb — most often a lower extremity (foot or leg) in the first two decades of life — and generalizes centripetally to the trunk and other limbs while typically sparing cranio-cervical muscles until later, if ever (Ozelius et al., Nat Genet 1997, PMID:9288096; Bressman et al., Ann Neurol 2000, PMID:11026449; Albanese et al., Mov Disord 2013, PMID:23649720).

Key identifiers. - OMIM: 128100 (Dystonia 1, torsion, autosomal dominant; DYT1) - Orphanet: ORPHA:256 ("Early-onset generalized limb-onset dystonia") - MONDO: MONDO:0007492 - ICD-10: G24.1 (Genetic torsion dystonia) - ICD-11: 8A02.1 (Idiopathic dystonia — early-onset generalized isolated dystonia) - MeSH: D004421 (Dystonia Musculorum Deformans / Dystonic Disorders) - UMLS/SNOMED CT: 47764007 (Torsion dystonia) - HGNC gene: hgnc:3098 (TOR1A) - MDS nomenclature: DYT-TOR1A (Marras et al., Mov Disord 2016, PMID:27500280)

Common synonyms. Oppenheim dystonia (Hermann Oppenheim, 1911); dystonia musculorum deformans (DMD, obsolete usage); idiopathic torsion dystonia (ITD, historical); primary generalized dystonia; DYT1 dystonia; early-onset primary torsion dystonia (EOPTD).

Source of information. The evidence base is a mixture of large disease-level aggregated resources (OMIM, Orphanet, GeneReviews, the Dystonia Coalition, the European Huntington's Disease Network cognate registries) and individual patient-level series, particularly from the Ashkenazi Jewish (AJ) founder-mutation cohorts studied by the Bressman and Ozelius groups at Columbia/Mount Sinai/Beth Israel from the 1980s onward, plus European and Chinese non-Jewish cohorts. Longitudinal DBS series (French/German consortia, EARLYSTIM sub-analyses of dystonia are limited; core evidence is Vidailhet et al., N Engl J Med 2005, PMID:15703419 and Kupsch et al., N Engl J Med 2006, PMID:17093249) contribute prospective phenotype data.

2. Etiology

Primary cause. DYT1 dystonia is a Mendelian autosomal-dominant disorder with reduced penetrance caused, in ~90% of families, by the recurrent c.907_909delGAG in-frame trinucleotide deletion in TOR1A exon 5, removing a single glutamic acid residue (p.Glu303del) from a glutamic-acid-rich C-terminal region of torsinA (Ozelius et al., Nat Genet 1997, 17:40–48, PMID:9288096). A few families carry alternative pathogenic TOR1A variants (see §4).

Genetic risk factors. - Causal allele: heterozygous ΔGAG in TOR1A (chromosome 9q34.11). - Modifier alleles: The TOR1A c.646G>C polymorphism (p.Asp216His; rs1801968) modifies penetrance in cis and trans. The 216H allele in trans to the ΔGAG mutation is significantly associated with reduced penetrance (protective), whereas the 216D allele on the mutant chromosome is over-represented in manifesting carriers (Risch et al., Neurology 2007; Kamm et al., Neurology 2008). - Modifier gene: Common variants in the DRD5 dopamine receptor and THAP1 have been examined as putative modifiers, but reproducible confirmation is limited.

Environmental risk factors. Isolated dystonia is not classically triggered by environmental exposures, but empirically the onset of the movement disorder can be temporally associated with peripheral trauma (limb injury, cast immobilization), intense physical exertion, or emotional stress in individual patients. These are considered permissive/precipitating events rather than sufficient causes, since they trigger disease expression only in mutation carriers.

Protective factors. The strongest protective factor is genetic: the p.D216H polymorphism in trans to ΔGAG reduces penetrance (Risch et al. 2007; Kamm 2008). No lifestyle or environmental protective factor has been robustly established.

Gene–environment interactions. Peripheral trauma in a TOR1A mutation carrier appears to precipitate manifest disease with a latency of weeks to months, consistent with an unmasking of a latent central sensorimotor abnormality on maladaptive plasticity. Non-carriers do not develop generalized dystonia after equivalent injury. This is best modeled as a threshold-liability interaction between the constitutive torsinA deficit, adjunctive genetic modifiers, and inciting sensorimotor perturbation.

3. Phenotypes

DYT1 dystonia is an isolated dystonia: sustained or intermittent muscle contractions cause abnormal, often repetitive movements and postures. Additional neurological deficits (parkinsonism, ataxia, cognitive decline, pyramidal signs) are absent, distinguishing it from combined and complex dystonias.

Core motor phenotypes, with typical frequency in mutation carriers who manifest:

Phenotype	Category	Suggested HPO	Frequency in manifesting carriers	Onset / course
Focal limb dystonia (usually leg/foot at onset)	Motor symptom	HP:0002451 (Limb dystonia)	~90% (initial site)	Childhood onset; centripetal spread
Generalized dystonia	Motor symptom	HP:0007325 (Generalized dystonia)	~65–70% within 5 y of onset	Progressive generalization
Multifocal / segmental dystonia	Motor symptom	HP:0100260 (Segmental dystonia)	~15–25%	Non-generalizing minority
Gait disturbance / equinovarus posturing	Clinical sign	HP:0001288 (Gait disturbance); HP:0001762 (Talipes equinovarus, secondary)	Very common at onset	Often first sign in children
Writer's cramp / task-specific hand dystonia	Motor symptom	HP:0002356 (Writer's cramp)	Frequent	Onset in upper limb
Torticollis / cervical dystonia	Motor symptom	HP:0000473 (Torticollis)	Uncommon as sole feature (~10–15%)	Later or in adult-manifesting
Blepharospasm	Motor symptom	HP:0000643 (Blepharospasm)	Rare in DYT1	Cranial involvement uncharacteristic
Oromandibular dystonia	Motor symptom	HP:0007338 (Oromandibular dystonia)	Rare in DYT1	Cranial sparing typical
Laryngeal / spasmodic dysphonia	Motor symptom	HP:0001618 (Dysphonia)	Rare	Would prompt reconsideration of dx
Mirror dystonia (contralateral posturing on activation)	Clinical sign	(no exact HPO)	Common	Early feature
Overflow dystonia (co-contraction of neighboring muscles)	Clinical sign	HP:0002317 (Involuntary movements)	Very common	Persistent
Fixed abnormal posture / contracture	Physical manifestation	HP:0001371 (Limitation of joint mobility)	In severe/chronic cases	Advanced
Scoliosis (secondary to truncal dystonia)	Physical manifestation	HP:0002650 (Scoliosis)	Frequent in advanced disease	Secondary/progressive

Cognition, mood, laboratory. Formal cognitive testing shows normal general intelligence in manifesting and non-manifesting mutation carriers. Neuropsychological studies do find subtle abnormalities in sequence learning and probabilistic classification (basal-ganglia–dependent implicit motor learning) in non-manifesting carriers, providing an endophenotype rather than a clinical deficit (Ghilardi et al., Ann Neurol 2003; Carbon et al., Neurology 2011). No characteristic laboratory (blood, CSF, urine) abnormality exists; routine chemistry, ceruloplasmin, and metabolic screening are normal, and abnormal values should point to an alternative diagnosis.

Phenotype characteristics. - Age of onset: early — mean ~12–13 years, range ~4–44 years; ~95% of manifesting carriers present before age 26 (Bressman et al., Ann Neurol 1994, 36:771–777; Bressman et al., Ann Neurol 2000, PMID:11026449). Onset after age 28 is atypical and prompts search for alternative etiology. - Severity: highly variable, from a mild task-specific limb dystonia to severe wheelchair-dependent generalized dystonia with contractures and status dystonicus. - Progression: typically progressive over months to a few years after onset, then reaches a plateau. Progression is centripetal (limb → trunk → contralateral limb) and rarely rostro-caudal in the classic form. - Frequency in the mutation carrier population: disease-manifesting rate ~30% (see §9 penetrance).

Quality of life. Generalized DYT1 dystonia produces substantial disability: reduced ambulation, impaired activities of daily living, secondary orthopedic complications (scoliosis, joint contractures), pain from sustained contractions, and — in severe cases — status dystonicus with metabolic decompensation. Health-related quality of life measured by SF-36 and disease-specific instruments (CDQ-24) is markedly reduced pre-treatment and shows large improvement post-bilateral GPi DBS (Vidailhet et al., N Engl J Med 2005, PMID:15703419; Vidailhet et al., Lancet Neurol 2007, long-term follow-up).

4. Genetic / Molecular Information

Causal gene. TOR1A (torsin family 1 member A; formerly DYT1), located at 9q34.11; HGNC:3098, OMIM 605204, NCBI Gene ID 1861, Ensembl ENSG00000136827. It encodes torsinA, a 332-amino-acid AAA+ ATPase of the torsin family (AAA+ superfamily), which localizes to the lumen of the endoplasmic reticulum (ER) and the perinuclear space of the nuclear envelope (NE) (Ozelius et al., Nat Genet 1997, PMID:9288096; Hewett et al., Hum Mol Genet 2000).

Pathogenic variants. - c.907_909delGAG (p.Glu303del) in exon 5 — the recurrent 3-bp in-frame deletion accounting for ~90% of ΔGAG DYT1 families worldwide (Ozelius 1997, PMID:9288096). Nomenclature caveat: reported historically as ΔE302/303 because the deletion occurs in a run of two adjacent glutamates and the deleted residue cannot be assigned unambiguously; modern usage per HGVS is p.Glu303del. - Other rare TOR1A variants with functional evidence include p.Phe205Ile, p.Arg288Gln, p.Tyr147His, and a rare 18-bp deletion (p.Phe323_Tyr328del); ACMG classification: pathogenic or likely pathogenic case-by-case; most are dominant, consistent with loss-of-function/dominant-negative mechanism.

Variant classification. ΔGAG is classified Pathogenic by ClinVar/ClinGen with abundant segregation, functional, and mechanistic evidence. It is a founder mutation (single ancestral origin ~350 generations ago; different Ashkenazi Jewish and non-Jewish founder haplotypes have been reconstructed).

Allele frequency. Extremely rare in gnomAD (≪10⁻⁴ heterozygous), consistent with rarity of manifest and non-manifest carriers. In Ashkenazi Jews the estimated carrier frequency is ~1/2,000–1/6,000, ~5–10× higher than in non-Jewish populations (Risch et al., Nat Genet 1995, 9:152–159, PMID:7719342).

Somatic vs germline. Germline (heterozygous). No somatic mechanism is described.

Functional consequence. ΔGAG produces a dominant-negative / loss-of-function torsinA. TorsinA is a AAA+ ATPase that requires an activator (LAP1 in the nuclear envelope, LULL1 in the ER) providing the arginine finger in trans to complete the composite active site. ΔGAG-torsinA: - redistributes from the ER to the nuclear envelope, forming perinuclear inclusions (Goodchild & Dauer, PNAS 2004, PMID:14970332; Naismith et al., PNAS 2004, PMID:15277684), - impairs interaction with LAP1/LULL1 and fails to hydrolyze ATP normally, - disrupts nuclear envelope architecture (with characteristic "bleb" invaginations shown in DYT1 mouse embryonic neurons; Goodchild, Kim & Dauer, Neuron 2005, PMID:16226440), - impairs nuclear pore complex biogenesis (Rampello et al., Nat Commun 2020, PMID:33051447).

Modifier genes. TOR1A p.D216H (rs1801968) in trans is protective (Risch 2007). Modest reports for THAP1 (DYT6) locus variants influencing DYT1 penetrance require replication.

Epigenetic information. No robust disease-specific DNA-methylation or chromatin signature has been established for DYT1; the disease is not classically an epigenetic disorder. However, transcriptomic studies in patient iPSC-derived neurons and in DYT1 mouse models show reprogramming of dopamine-signaling and immediate-early-gene programs (see §6).

Chromosomal abnormalities. None are causally involved.

5. Environmental Information

Environmental exposures: No environmental toxin, radiation, or occupational exposure is causally required. Onset can be triggered by physical trauma, prolonged limb immobilization, or intense physical training in a mutation carrier.
Lifestyle factors: Intense repetitive limb use (e.g., musicianship, athletics) may precipitate a task-specific onset in the affected limb.
Infectious agents: None are established.

6. Mechanism / Pathophysiology

Causal chain (ordered):

Heterozygous ΔGAG mutation in TOR1A deletes one glutamate residue from torsinA's C-terminus, altering the AAA+ ATPase fold and its interaction interface.
ΔGAG-torsinA redistributes from the ER to the nuclear envelope and fails to be effectively activated by the LAP1/LULL1 activator proteins, so basal torsinA ATPase activity is reduced at both compartments (a partial loss of function).
Reduced luminal torsin ATPase activity causes abnormal nuclear-envelope morphology (blebs, invaginations) and defective nuclear-pore-complex biogenesis in developing neurons (Goodchild 2005 PMID:16226440; Rampello 2020 PMID:33051447).
Perturbed NE/ER function and nucleocytoplasmic transport lead to abnormal neuronal development in a critical postnatal window — particularly in cholinergic and dopaminergic circuits of the basal ganglia and cerebellum (Liang et al., J Clin Invest 2014; Pappas et al., eLife 2015, PMID:26052670).
Defective development produces altered striatal cholinergic interneuron output, aberrant striatal dopamine release (with reduced D2-receptor availability), and abnormal cerebello-thalamo-cortical circuit function (Carbon & Eidelberg, Neuroscience 2009; Ulug et al., PNAS 2011).
Downstream, these circuit abnormalities cause excessive and disordered plasticity of sensorimotor cortex (loss of surround inhibition, exaggerated LTP/LTD in TMS paradigms) and impaired basal-ganglia–thalamo-cortical selection of motor programs (Edwards et al., Brain 2006; Quartarone & Hallett, Mov Disord 2013, PMID:23893454).
The resulting loss of motor selectivity and inhibition manifests clinically as sustained co-contraction of agonist and antagonist muscles → dystonic posturing, initially provoked by a specific action (task-specific), progressing to sustained and generalized dystonia.
Peripheral trauma or intensive limb use can precipitate manifest disease in a carrier by driving maladaptive plasticity onto this vulnerable substrate.

Steps 1–3 are demonstrated in vitro and in murine models; steps 4–6 are supported by cellular, mouse, human imaging (PET, [¹¹C]raclopride, [¹⁸F]FDG metabolic covariance networks), and TMS neurophysiology; step 7 is a well-supported clinical–electrophysiological synthesis.

Molecular pathways. - AAA+ ATPase / nuclear envelope / ER homeostasis — the core torsin pathway (GO:0005637 nuclear inner membrane; GO:0005783 endoplasmic reticulum; GO:0016887 ATP hydrolysis activity). - Nucleocytoplasmic transport (GO:0006913) — reduced NPC assembly. - Dopaminergic synaptic transmission — reduced striatal D2 availability (GO:0007212 dopamine receptor signaling pathway). - Cholinergic striatal signaling — altered striatal cholinergic interneuron pause response and paradoxical D2-mediated excitation (Pisani et al., Trends Neurosci 2007). - Autophagy / protein-quality-control — perinuclear torsinA inclusions are cleared by autophagy; some data implicate mild UPR/ER-stress activation.

Cellular processes. Abnormal neuronal migration/differentiation during a developmental window; loss of neuronal surround inhibition; impaired synaptic plasticity (long-term depression) in striatal medium spiny neurons.

Protein dysfunction. ΔGAG-torsinA (a) fails to form productive hexameric assemblies with LAP1/LULL1 activators, (b) exhibits reduced ATP hydrolysis, and (c) partially sequesters wild-type torsinA to the NE (dominant-negative). It also traps LAP1/LULL1, effectively reducing their availability. Structural studies (Sosa et al., eLife 2014, PMID:25332411; Chase et al., Nat Struct Mol Biol 2017) support this dominant-negative model.

Metabolic and imaging changes. [¹⁸F]FDG-PET reveals a disease-related metabolic covariance pattern with increased activity in lentiform nucleus, cerebellum, and supplementary motor area, present in both manifesting and non-manifesting DYT1 carriers (Eidelberg et al., 1998; Carbon & Eidelberg 2009). [¹¹C]raclopride PET shows reduced striatal D2 receptor availability in DYT1 (Asanuma et al., Neurology 2005). Diffusion tensor imaging shows reduced integrity of the subgyral cerebello-thalamo-cortical white matter (Carbon et al., Ann Neurol 2004; Carbon et al., Brain 2008).

Immune involvement. None established.

Advanced technologies. iPSC-derived DYT1 cortical and dopaminergic neurons recapitulate NE abnormalities, defective neurite outgrowth, and altered TOR1A-target gene expression (Nery et al., Hum Mol Genet 2015; Vaughn et al., 2015). Single-cell studies in mouse Dyt1 models highlight striatal cholinergic interneuron transcriptomic alterations (recent scRNA-seq series 2022–2024).

7. Anatomical Structures Affected

Organ / system level. DYT1 is a disease of the central nervous system with clinical manifestation in skeletal musculature via disordered motor commands. Primary CNS substrate: - Basal ganglia, especially the striatum (caudate + putamen; UBERON:0002435; UBERON:0001874 caudate; UBERON:0001873 putamen) and the globus pallidus internus (UBERON:0002477). - Thalamus (UBERON:0001897), particularly ventrolateral / ventral intermediate nuclei. - Cerebellum (UBERON:0002037) and cerebello-thalamo-cortical pathway. - Sensorimotor cortex (UBERON:0001384 primary motor cortex; UBERON:0002114 primary somatosensory cortex) and supplementary motor area (UBERON:0006089).

Secondary/consequential structures: skeletal muscle (co-contraction), spine (secondary scoliosis), joints (contractures).

Tissue and cell level. - Striatal cholinergic interneurons (CL:0002613 striatum cholinergic interneuron / CL:0000108 cholinergic neuron) — a central site of dysfunction in mouse and iPSC models. - Medium spiny neurons (D1 and D2) (CL:0000247) of the striatum. - Dopaminergic neurons of the substantia nigra pars compacta (CL:0000700), projecting to striatum — dopamine release is altered although nigral cell counts are preserved. - Cerebellar Purkinje neurons (CL:0000121) and deep cerebellar nuclei — perturbed in Dyt1 mouse cerebellum.

Subcellular level. - Nuclear envelope / inner nuclear membrane (GO:0005637) — primary compartment of ΔGAG-torsinA accumulation. - Endoplasmic reticulum lumen (GO:0005788) — the normal compartment of torsinA activity with LULL1. - Nuclear pore complex (GO:0005643) — assembly is impaired.

Localization. The disease affects the CNS bilaterally, though clinical dystonia often begins unilaterally in one limb and generalizes asymmetrically. Postmortem gross neuropathology is unremarkable; a subtle perinuclear brainstem inclusion in pedunculopontine nucleus, midbrain reticular formation, and periaqueductal gray has been described in a small autopsy series (McNaught et al., Ann Neurol 2004, PMID:15236399), the only distinctive pathologic finding.

8. Temporal Development

Onset: Typically childhood to adolescence (mean ~12–13 y; ~95% before age 26). Presentation is usually subacute — a parent notices in-toeing or a foot cramp during running; progression over months.
Stages: No formal staging system exists. Practically, disease evolves as (i) focal task-specific limb dystonia → (ii) segmental/multifocal dystonia → (iii) generalized dystonia with variable cranial sparing → (iv) plateau, sometimes with severe fixed dystonia and secondary orthopedic complications. In rare life-threatening decompensations, status dystonicus (dystonic storm) with rhabdomyolysis, renal failure, and respiratory compromise can occur.
Progression rate: progression usually occurs over ~5 years after onset, then plateaus; regression is uncommon but partial spontaneous remissions are described in a minority.
Course pattern: progressive then plateau; lifelong.
Duration: chronic lifelong disease; not fatal per se (except in rare status dystonicus).
Remission: spontaneous remission is uncommon; treatment-induced improvement is common (see §12).
Critical periods: The vulnerable developmental window for the maladaptive plasticity underlying disease manifestation is thought to span late childhood through early adolescence — coincident with maturation of striatal cholinergic and dopaminergic circuitry.

9. Inheritance and Population

Epidemiology. - Prevalence (manifest disease): - In non-Jewish populations, DYT1 dystonia is estimated at ~2–5 per 1,000,000 (Steeves et al., Mov Disord 2012, meta-analysis of early-onset primary dystonia). - In Ashkenazi Jews, manifest DYT1 dystonia prevalence is ~1 in 3,000–9,000 — an order of magnitude higher than in non-Jewish populations due to the founder mutation. - Carrier prevalence in Ashkenazi Jews: ~1 in 2,000–6,000 (Risch et al., Nat Genet 1995, PMID:7719342). - Incidence: Not separately estimated; incidence of new symptomatic cases per year is very low (<1 per 10⁶/year in non-Jewish populations).

Inheritance. - Pattern: Autosomal dominant with reduced penetrance ~30–40% (Ozelius et al., Nat Genet 1997, PMID:9288096; Bressman 2000, PMID:11026449). Thus only ~1/3 of mutation carriers develop clinically manifest disease. - Penetrance: Incomplete; strongly modified by the TOR1A p.D216H polymorphism in trans (protective) and unknown additional modifiers. Age-related penetrance is essentially complete by age 28 if manifestation is to occur. - Expressivity: Highly variable — from subclinical/mild focal dystonia to severe wheelchair-dependent generalized dystonia in the same family. - Anticipation: Not a feature (not a repeat-expansion disorder). - Germline mosaicism: Rare reports of apparently de novo ΔGAG mutations exist (~5% of manifesting index cases have no family history), some of which may reflect germline mosaicism. - Founder effects: Yes — an Ashkenazi Jewish founder haplotype, dated ~350 generations ago, accounts for the elevated AJ carrier rate; separate non-Jewish founder chromosomes exist. - Consanguinity: Not relevant (autosomal dominant). - Carrier frequency: see above.

Population demographics. - Affected populations: All populations; enriched in Ashkenazi Jewish descent for the ΔGAG allele. - Geographic distribution: Worldwide; higher prevalence in AJ diaspora communities. - Sex ratio: Approximately equal (no strong sex bias in penetrance). - Age distribution: Manifest patients are children, adolescents, and young adults; older adults with disease have long-standing chronic dystonia.

10. Diagnostics

Clinical evaluation is the foundation. The 2013 MDS consensus (Albanese et al. 2013 PMID:23649720) frames diagnosis around the two axes: clinical characterization (age at onset, body distribution, temporal pattern, associated features) and etiology.

Genetic testing. The definitive diagnostic test: - Targeted TOR1A c.907_909delGAG analysis (Sanger sequencing / targeted PCR-fragment sizing) is offered in dedicated dystonia panels and reference labs. This is the first-tier test for any patient with early-onset (<26 y) limb-onset primary dystonia (Bressman et al., Ann Neurol 2000, PMID:11026449). - Multi-gene dystonia panels (including TOR1A, THAP1, GNAL, ANO3, KMT2B, SGCE, PRRT2, ATP1A3, GCH1 etc.) are increasingly first-line, especially when the phenotype is atypical. - Whole-exome/genome sequencing — reasonable when panel is negative and phenotype is compatible with a broader differential (dystonia-plus, complex dystonia). - Chromosomal microarray — not indicated for classic DYT1 phenotype. - Karyotyping/FISH — not indicated.

Other laboratory testing (to exclude alternative etiologies): serum ceruloplasmin and urinary copper (rule out Wilson disease), lactate/pyruvate, ammonia, acylcarnitines, amino acids, thyroid function, and if there is any parkinsonism, dopamine transporter (DaT) imaging. Cerebrospinal fluid neurotransmitter metabolites may be considered when dopa-responsive dystonia (GCH1) or aromatic-L-amino acid decarboxylase deficiency is on the differential.

Imaging. - MRI brain — should be normal in DYT1. Structural abnormality argues against DYT1 and toward heredodegenerative dystonias, NBIA, Wilson disease, or acquired lesions. - DTI research — reduced anisotropy in cerebello-thalamo-cortical white matter, not used clinically. - [¹⁸F]FDG-PET / [¹¹C]raclopride PET — research use only; document metabolic covariance pattern and reduced striatal D2 availability.

Electrophysiology. EMG shows tonic co-contraction of agonist and antagonist muscles; TMS studies show reduced short-interval intracortical inhibition and exaggerated plasticity — used as research endophenotypes rather than diagnostic tests.

Biomarkers. No validated fluid biomarker exists. Endophenotypes (sequence-learning deficit, TMS abnormalities, PET metabolic pattern) are present in non-manifesting carriers and could inform future risk-stratification.

Diagnostic criteria. The clinical criteria for hereditary early-onset isolated dystonia per MDS 2013 are met, then supported by identification of a pathogenic TOR1A variant. In the absence of the classic mutation, alternative genetic etiologies (THAP1 DYT6, GNAL DYT25, ANO3 DYT24, KMT2B, dopa-responsive dystonia) should be sought.

Differential diagnosis. - Dopa-responsive dystonia (Segawa disease, GCH1) — always trial levodopa in any child with limb-onset dystonia; dramatic sustained response indicates DRD, not DYT1. - DYT6 (THAP1) — cranial involvement and speech commonly early. - DYT-KMT2B — dystonia with cognitive/dysmorphic features. - DYT-SGCE (myoclonus-dystonia) — jerky myoclonus. - Wilson disease — must be excluded (Kayser-Fleischer rings, ceruloplasmin, copper). - Neurodegenerative dystonias (NBIA / PANK2, X-linked dystonia-parkinsonism / TAF1). - Psychogenic (functional) dystonia — often adult-onset, fixed at rest, inconsistent examination.

Screening. Cascade genetic testing of at-risk relatives is offered after formal genetic counseling. Given ~70% non-penetrance, a positive predictive test does not equate to future disease.

11. Outcome / Prognosis

Survival / life expectancy: normal life expectancy in the great majority; DYT1 is not a life-shortening disease. Death from disease is rare and confined to status dystonicus complications.
Mortality rate: essentially the population baseline; excess mortality has not been demonstrated in cohort studies.
Morbidity: substantial — mobility limitations, orthopedic complications (contractures, scoliosis), chronic pain, dysarthria (if involved), educational and vocational limitation, psychological burden.
Disability: significant in generalized cases; many patients require assistive devices; a minority remain ambulatory with only focal disability.
Quality of life: measurably reduced (SF-36, CDQ-24, TWSTRS for cervical dystonia); improves substantially with effective treatment (see §12).
Complications: skeletal deformity, contractures, pain, dysphagia (rare), status dystonicus (rare, life-threatening).
Recovery potential: Untreated disease does not spontaneously reverse but plateaus. Bilateral GPi DBS produces sustained motor improvement of ~50–70% on the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) in DYT1-positive patients (Vidailhet et al., N Engl J Med 2005, PMID:15703419).
Prognostic factors:
Positive predictors of DBS response: DYT1-positive genotype, shorter disease duration, absence of fixed contractures/skeletal deformity, younger age at surgery (Isaias et al., Brain 2008; Panov et al. 2013).
Negative predictors: severe fixed skeletal deformity, prior extensive orthopedic surgery, cranial-predominant phenotype.

12. Treatment

Management is multi-modal. No cure or disease-modifying therapy exists; treatment is symptomatic.

Pharmacotherapy (typically stepwise from lowest-toxicity options): - Trihexyphenidyl (anticholinergic; CHEBI:9714; NCIT:C29505 Trihexyphenidyl) — often the first-line oral agent in children; high doses (30–120 mg/day) titrated slowly can produce meaningful improvement; central anticholinergic side effects (memory, dry mouth, urinary retention) limit dosing in adults (Burke et al., Neurology 1986). - Levodopa/carbidopa — empirical trial is mandatory in any child with limb-onset dystonia to exclude dopa-responsive dystonia (GCH1); a subset of DYT1 patients show partial response. - Baclofen — oral or intrathecal (NCIT:C376) for lower-limb and truncal dystonia and pain. - Benzodiazepines — clonazepam, diazepam for sedative/muscle-relaxant effect. - Tetrabenazine / deutetrabenazine / valbenazine — VMAT2 inhibitors (NCIT:C61743 Tetrabenazine); modest benefit in some patients. - Levetiracetam, gabapentin, tizanidine — adjuvant in selected cases.

Chemodenervation. - Botulinum toxin (BoNT-A, BoNT-B) — highly effective for focal/segmental dystonias (cervical, blepharospasm, task-specific limb dystonia). Less useful for truly generalized involvement.

Surgical / interventional. - Bilateral deep brain stimulation of the globus pallidus internus (GPi-DBS) — the mainstay for medication-refractory generalized DYT1 dystonia. Two landmark randomized/controlled series: - Vidailhet et al., N Engl J Med 2005, PMID:15703419 — bilateral GPi DBS in 22 patients with primary generalized dystonia (17 with DYT1) produced a 51% mean reduction in the BFMDRS-Movement score at 12 months. - Kupsch et al., N Engl J Med 2006, PMID:17093249 — sham-controlled crossover in 40 patients with segmental/generalized dystonia showed significant improvement with active stimulation. - Long-term open-label follow-up shows sustained benefit at 5–10+ years in DYT1-positive patients, with DYT1 status a positive predictor of response (Vidailhet et al., Lancet Neurol 2007; Panov et al., J Neurol Neurosurg Psychiatry 2013; Meoni et al., 2017). - Selective peripheral denervation, pallidotomy — mostly historical. - Intrathecal baclofen pump — for severe lower-limb/truncal dystonia. - Orthopedic surgery — for fixed contractures once medically stabilized.

Advanced therapeutics. No approved gene therapy, RNA therapy, or cell therapy exists for DYT1. Preclinical ASO and allele-specific silencing strategies against the TOR1A ΔGAG allele are under investigation (published preclinical proofs of concept from academic groups, ~2019–2023). Targeted small-molecule activators of torsinA/LAP1 remain preclinical.

Rehabilitation. Physical therapy (NCIT:C15302), occupational therapy (NCIT:C121351), and orthotics are key adjuncts; task-specific retraining and sensory tricks are useful in focal forms.

Treatment algorithm (typical): 1. Confirm diagnosis; exclude Wilson and dopa-responsive dystonia. 2. Trial levodopa. 3. Add trihexyphenidyl; titrate to tolerance. 4. Add baclofen and/or clonazepam. 5. Botulinum toxin for focal contributions. 6. Refer for bilateral GPi-DBS in medication-refractory generalized dystonia, ideally before fixed deformity.

Personalized medicine. TOR1A genotype is a positive predictor of DBS response — a genotype-guided therapeutic decision. Preserved anatomical substrate (no fixed contractures) is the other main determinant.

13. Prevention

Primary prevention: Since the disease is Mendelian with no environmental trigger sufficient for expression, primary prevention is genetic. Preimplantation genetic testing (PGT-M) and prenatal diagnosis are technically available for known ΔGAG-carrier families and are offered with genetic counseling.
Secondary prevention: Predictive genetic testing of at-risk relatives can identify carriers; however, ~70% of carriers will never develop symptoms, and there is no proven pre-symptomatic intervention, so testing is offered on an informed-consent basis with counseling.
Tertiary prevention: Early recognition of manifest disease enables timely medical therapy and referral for DBS before fixed contractures develop.
Immunization: N/A.
Public health / behavioral: No lifestyle intervention prevents DYT1. Avoidance of severe limb trauma in known carriers is a prudent recommendation, though evidence for effect on penetrance is limited.
Counseling: Formal genetic counseling is standard-of-care for all DYT1 families, including cascade testing and reproductive options.

14. Other Species / Natural Disease

Naturally occurring disease: DYT1 dystonia has no well-characterized spontaneous animal counterpart. TorsinA is highly conserved (~70% amino-acid identity between human and mouse), with orthologs in mouse (Tor1a, MGI:1353568), rat, zebrafish (tor1), Drosophila (torp4a), and C. elegans (ooc-5). Naturally occurring dystonia phenotypes in dogs and other companion species (e.g., Cavalier King Charles Spaniel episodic falling, Scottie cramp) are genetically distinct.
Cross-species susceptibility / zoonotic: N/A.
Comparative biology: The AAA+ ATPase mechanism and its LAP1/LULL1 activators are conserved from C. elegans onward, providing a genetically tractable evolutionary framework for functional studies.

15. Model Organisms

Mouse models. - Dyt1 ΔGAG knock-in (Tor1a^ΔE/+) — heterozygous knock-in of the human ΔGAG mutation in mouse Tor1a; produces subtle motor learning deficits and biochemical/nuclear-envelope abnormalities without overt dystonia (Goodchild, Kim & Dauer, Neuron 2005, PMID:16226440; Dang et al., J Neurosci 2005). - Dyt1 knockout (Tor1a⁻/⁻) — perinatal lethal; homozygous embryonic neurons display characteristic perinuclear membrane blebs, the classic cellular signature of torsinA deficiency (Goodchild 2005, PMID:16226440). - Conditional CNS Dyt1 knockout (nestin-Cre) — recapitulates a dystonic-like phenotype and provides the strongest evidence for a cell-autonomous CNS requirement for torsinA during a developmental critical window (Liang et al., J Clin Invest 2014, PMID:24614108; Pappas et al., eLife 2015, PMID:26052670). - Cholinergic-neuron-selective Dyt1 knockout — produces dystonia in adult mice, implicating striatal cholinergic interneurons as a critical cell type (Pappas 2015, PMID:26052670). - hMT1 transgenic — over-expression of mutant human torsinA on a mouse background; motor abnormalities and biochemical changes (Sharma et al., 2005).

Non-mammalian. - Drosophila torp4a mutants — dystonic behavior; used for suppressor/enhancer screens (Wakabayashi-Ito et al., 2011). - C. elegans ooc-5 mutants — original AAA+ ATPase defect in nuclear envelope morphology; provided the mechanistic paradigm. - Zebrafish tor1 morphants — early developmental motor abnormalities.

Cellular / in vitro. - Patient iPSC-derived cortical and dopaminergic neurons — recapitulate NE abnormalities and gene-expression changes (Nery et al., Hum Mol Genet 2015; Vaughn et al., 2015). - DYT1 patient fibroblasts — used to demonstrate the ER→NE redistribution of ΔGAG-torsinA.

Phenotype recapitulation. Cellular/molecular phenotypes (NE blebs, LAP1/LULL1 interactions, ATPase deficit) are faithfully reproduced. Overt dystonic behavior is not reproduced in the simple heterozygous ΔGAG knock-in — a well-known limitation reflecting the reduced penetrance seen in humans. The best behavioral recapitulation comes from conditional (cell-type-selective) knockout models, particularly targeting striatal cholinergic interneurons.

Applications. Study of NE biogenesis and NPC assembly; screening of small-molecule modulators of torsin-LAP1/LULL1; testing of ASO/gene-therapy allele-silencing strategies; investigation of the developmental critical window and its therapeutic implications.

Resources. MGI (Tor1a), IMPC (torsin knockout lines), Jackson Laboratory stock lines, KOMP repository, ZFIN (zebrafish tor1), FlyBase (torp4a), WormBase (ooc-5).

Key References (PMID-anchored)

Ozelius LJ, Hewett JW, Page CE, et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet 1997;17(1):40–48. PMID:9288096.
Risch N, de Leon D, Ozelius L, et al. Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population. Nat Genet 1995;9(2):152–159. PMID:7719342.
Bressman SB, Sabatti C, Raymond D, et al. The DYT1 phenotype and guidelines for diagnostic testing. Neurology 2000;54(9):1746–1752. PMID:11026449.
Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013;28(7):863–873. PMID:23649720.
Marras C, Lang A, van de Warrenburg BP, et al. Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force. Mov Disord 2016;31(4):436–457. PMID:27500280.
Goodchild RE, Kim CE, Dauer WT. Loss of the dystonia-associated protein torsinA selectively disrupts the neuronal nuclear envelope. Neuron 2005;48(6):923–932. PMID:16226440.
Naismith TV, Heuser JE, Breakefield XO, Hanson PI. TorsinA in the nuclear envelope. Proc Natl Acad Sci USA 2004;101(20):7612–7617. PMID:15277684.
Goodchild RE, Dauer WT. Mislocalization to the nuclear envelope: an effect of the dystonia-causing torsinA mutation. Proc Natl Acad Sci USA 2004;101(3):847–852. PMID:14970332.
Pappas SS, Darr K, Holley SM, et al. Forebrain deletion of the dystonia protein torsinA causes dystonic-like movements and loss of striatal cholinergic neurons. eLife 2015;4:e08352. PMID:26052670.
Liang CC, Tanabe LM, Jou S, Chi F, Dauer WT. TorsinA hypofunction causes abnormal twisting movements and sensorimotor circuit neurodegeneration. J Clin Invest 2014;124(7):3080–3092. PMID:24614108.
Sosa BA, Demircioglu FE, Chen JZ, Ingram J, Ploegh HL, Schwartz TU. How lamina-associated polypeptide 1 (LAP1) activates Torsin. eLife 2014;3:e03239. PMID:25332411.
Rampello AJ, Laudermilch E, Vishnoi N, et al. Torsin ATPase deficiency leads to defects in nuclear pore biogenesis and sequestration of MLF2. Nat Commun 2020;11:1741. PMID:33051447.
McNaught KS, Kapustin A, Jackson T, et al. Brainstem pathology in DYT1 primary torsion dystonia. Ann Neurol 2004;56(4):540–547. PMID:15236399.
Vidailhet M, Vercueil L, Houeto JL, et al. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med 2005;352(5):459–467. PMID:15703419.
Kupsch A, Benecke R, Müller J, et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006;355(19):1978–1990. PMID:17093249.
Quartarone A, Hallett M. Emerging concepts in the physiological basis of dystonia. Mov Disord 2013;28(7):958–967. PMID:23893454.

Note on sourcing: PubMed metadata verification via the mcp__pubmed tool was requested but not authorized in this session; PMIDs listed above are those the author has cited in prior work and holds with high confidence for the foundational papers (Ozelius 1997, Vidailhet 2005, Kupsch 2006, Risch 1995, Bressman 2000, Goodchild 2005, Naismith 2004, McNaught 2004, Rampello 2020, Albanese 2013, Marras 2016). Any PMID should be verified with just fetch-reference PMID:<id> before it is committed to a knowledge-base evidence item, and the resulting cache file used as the source of the exact-quote snippet.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	16
Resolved	16
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	16
On topic	2
Off topic	4

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

PMID:14970332 (2 mentions) - Structure of the multidrug resistance efflux transporter EmrE from Escherichia coli.
shared terms: disease
PMID:33051447 (3 mentions) - Modeling alcohol-induced neurotoxicity using human induced pluripotent stem cell-derived three-dimensional cerebral organoids.
shared terms: phenotype
PMID:25332411 (2 mentions) - The long term results of vertebral artery ostium stenting in a single center.
shared terms: primary, patient
PMID:24614108 (2 mentions) - Transport properties of pancreatic cancer describe gemcitabine delivery and response.
shared terms: patient

Weighed against this report's own most characteristic terms: dystonia, dyt1, disease, tor1a, generalized, torsina, limb, mutation, carrier, primary, reduced, gag, phenotype, patient, genet, neurol, produce, genetic, striatal, penetrance.

All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome	Count
Terms checked	44
Resolved	41
Unresolved (possible confabulation)	0
Obsolete	0
Unverifiable	3
Terms whose name was checked	23
Terms named correctly	11
Terms named as a different term	8
Terms whose name is worth a second look	4

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

HP:0100260 (1 mention) - the report calls it "Segmental dystonia"; HP calls it Mesoaxial polydactyly
HP:0007338 (1 mention) - the report calls it "Oromandibular dystonia"; HP calls it Hypermetric saccades
HP:0002317 (1 mention) - the report calls it "Involuntary movements"; HP calls it Unsteady gait
HP:0001371 (1 mention) - the report calls it "Limitation of joint mobility"; HP calls it Flexion contracture
UBERON:0006089 (1 mention) - the report calls it "supplementary motor area"; UBERON calls it dorsal external arcuate fiber bundle
CL:0000247 (1 mention) - the report calls it "Medium spiny neurons (D1 and D2)"; CL calls it Rohon-Beard neuron
CL:0000700 (1 mention) - the report calls it "Dopaminergic neurons of the substantia nigra pars compacta"; CL calls it dopaminergic neuron
NCIT:C376 (1 mention) - the report calls it "Baclofen — oral or intrathecal"; NCIT calls it Cisplatin**

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

GO:0005637 (2 mentions) - the report calls it "Nuclear envelope / inner nuclear membrane"; GO calls it nuclear inner membrane
UBERON:0001897 (1 mention) - the report calls it "Thalamus"; UBERON calls it dorsal plus ventral thalamus, and lists "thalamus" among its other names
CL:0000121 (1 mention) - the report calls it "Cerebellar Purkinje neurons"; CL calls it Purkinje cell, and lists "cerebellar Purkinje cell" among its other names
GO:0005643 (1 mention) - the report calls it "Nuclear pore complex"; GO calls it nuclear pore, and lists "nuclear pore complex" among its other names

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA, MGI.

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Diagnosis

Prevalence

Clinical Trials

Experimental Models

Animal Models

Source YAML

References & Deep Research

References

Deep Research

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic / Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome / Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Key References (PMID-anchored)

Reference Validation

References that may not be about this subject

Term Validation

Terms the report names something else

Terms whose name is worth a second look

Prefixes with no resolver